

12.13.99

SA Listing A

12/09/99



CERTIFICATION UNDER 37 CFR 1.10

I hereby certify that this Correspondence and the documents referred to as attached therein are being deposited with the United States Postal Service in an envelope as "Express Mail Post Office to Addressee" mailing Label Number EJ079901247US addressed to the: Commissioner of Patents and Trademarks, Washington, D.C. 20231, on the date typed below.

12/09/99  
Date

Joseph Davidenas  
Typed Name of Person  
Mailing Correspondence  
and Documents

[Signature]  
Signature of Person  
Mailing Correspondence  
and Documents

JC584 U.S. PTO  
09/454223



PATENT

Attorney's Docket No.: SD9-003-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Honorable Commissioner of  
Patents and Trademarks  
Washington, D.C. 20231

TRANSMITTAL OF UTILITY PATENT APPLICATION FOR FILING

Dear Sir:

Transmitted herewith for filing is the utility patent application of inventor Richard S. Kornbluth, entitled **MULTIMERIC FORMS OF TNF SUPERFAMILY LIGANDS**. Enclosed are:

- X\_ A duplicate copy of this transmittal letter.
- X\_ One stamped, self-addressed, postcard for the PTO Mail Room date stamp.
- X\_ One utility patent application containing pages 1 - 61 ,and
- X\_ a declaration or oath for the utility patent application including a power of attorney, and
- X\_ 1 copy of 7 sheets of informal drawings
- X\_ A verified statement relating to small entity status.

2. The filing fee has been calculated as shown below:

For:	No. Filed	No. Extra	Small Entity Rate	Fee
BASIC FEE				\$380
TOTAL CLAIMS	15 - 20 =	0	x \$ 9=	\$
INDEP. CLAIMS	8 - 3 =	0	x \$39=	\$195
MULTIPLE DEPENDENT CLAIM(S)			+\$120=	\$575

X\_ A check in the amount of \$575 to cover the filing fee is enclosed.

X\_ A duplicate copy of this letter is enclosed.

Sincerely yours,

*William C. Fuess*

William C. Fuess  
Registration No. 30,054  
Attorney for Applicant(s)

William C. Fuess  
Fuess & Davidenas  
Attorneys-at-Law  
10951 Sorrento Valley Rd.  
Suite II-G  
San Diego, California 92121-1223  
Telephone: (619) 452-8293  
Facsimile: (619) 452-8293

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Richard S. Kornbluth

Attorney's Docket No.: SD9-003-1

Title: **MULTIMERIC FORMS OF TNF SUPERFAMILY LIGANDS**

VERIFIED STATEMENT UNDER 37 CFR §1.9(f) and §1.27(d)  
CLAIMING STATUS AS A SMALL ENTITY -- NONPROFIT ORGANIZATION

I, William Fuess, attorney representative of inventor Richard Kornbluth and of the Technology Transfer Office of the University of California, San Diego, hereby declare that:

1. I am empowered to act on behalf of THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, a corporation duly organized under and pursuant to the laws of CALIFORNIA having its principal place of business at 300 Lakeside Drive, 22nd Floor, Oakland, California 94612-3550, in the matter of this VERIFIED STATEMENT.

2. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA is a University of higher education of the State of California and a nonprofit organization.

3. The rights under contract or law in the invention contained within above-identified patent application entitled **MULTIMERIC FORMS OF TNF SUPERFAMILY LIGANDS** have been assigned to and remain with THE REGENTS OF THE UNIVERSITY OF CALIFORNIA. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA has not assigned, granted, conveyed or licensed, and is under no obligation under contract or law to assign, grant, convey or license any rights in the invention nor in the application to any person who could not be classified as an independent inventor if that person had made the invention, or to any concern which would not qualify as a small business concern under 37 CFR §1.9(d) or a non-profit organization under 37 CFR §1.9(e).

4. THE REGENTS OF THE UNIVERSITY OF CALIFORNIA qualifies as a nonprofit organization as defined in 37 CFR §1.9, Subsection (e) for paying reduced fees under section 41 Subsections (a) and (b) of Title 35, United States Code, with regard to said application.

5. I acknowledge the duty under 37 CFR §1.28(b) to file, in this application or any patent issuing thereon, notification of any change in status resulting in loss of entitlement to small entity status prior to paying, or at the time of paying, the earliest of any issuance fee of any maintenance fee due after that date on which status as a small entity is no longer appropriate.

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements are made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under §1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent(s) issuing thereon.

December 9, 1999

Date

*William C. Fuen*

Signature of William Fuen

Attorney Representative

Technology Transfer Office

University of California, San Diego

9500 Gilman Drive, MC 0910

La Jolla, CA 92093-0093

Representative of THE REGENTS OF THE UNIVERSITY  
OF CALIFORNIA

Acting on behalf of THE REGENTS OF THE  
UNIVERSITY OF CALIFORNIA

300 Lakeside Drive, 22nd Floor

Oakland, CA 94612-3550

## MULTIMERIC FORMS OF TNF SUPERFAMILY LIGANDS

5

### BACKGROUND OF THE INVENTION

#### Field of the Invention

10           The present invention relates to a method form preparing soluble multimeric proteins consisting of more than three iterations of the same bioactive molecule using recombinant DNA technology.

15           The present invention particularly concerns a new method of producing multimeric fusion proteins involving the TNF superfamily (TNFSF) members as a fusion proteins with SPD, and more specifically, CD40L-SPD fusion proteins and useful modifications thereof.

#### Description of Related Art

20           Numerous proteins can be made using modern molecular biology techniques and used in diagnostic and therapeutic applications. Using recombinant DNA techniques, the DNA encoding a single amino acid chain is constructed and then introduced into a cell which manufactures the final protein. Some cells, especially bacteria like *E. coli*, lack the ability to properly fold the amino acid chains into the proper quaternary structure and they  
25           often fail to apply the necessary modifications (e.g., glycosylation and disulfide bond formation) that are needed for the protein to be bioactive and resistant to degradation *in vivo*.

While most of these challenges can be met by expressing the amino acid chain in eukaryotic cells like yeast or mammalian cells *in vitro*, it is not always straightforward to express proteins that consist of two or more amino acid chains. In general, for multichain proteins, the single amino acid chains must associate together in some way either within the producer cell or subsequently after the monomers are secreted from the producer cell. For artificially constructed molecules, the introduction into a single amino acid chain of an amino acid sequence which causes this chain-to-chain association can be an important step in producing multichain proteins.

One of the most widely used methods of causing two amino acid chains to associate is to conjoin, at the DNA coding level, segments from the protein of interest and a segment from a spontaneously dimerizing protein. The best example is to conjoin or fuse a protein with the Fc portion of immunoglobulin, creating a dimeric Fc fusion protein (Fanslow *et al.*, *J. Immunol.* 136:4099, 1986). A protein of this type can be formed from the extracellular domain of a tumor necrosis factor receptor fused to Fc (termed etanercept and marketed as ENBREL®), which is effective in the treatment of rheumatoid arthritis. A second example is the construction of a fusion protein between the dimerizing extracellular portion of CD8 with the extracellular portion of CD40L (Hollenbaugh *et al.*, *EMBO J.* 11:4313, 1992). Here, the dimerizing CD8 portion of the fusion protein helps to maintain the CD40L portion in the trimeric form needed for its bioactivity. A more recent example is the addition of an isoleucine zipper motif to CD40L, which permits the production of trimeric soluble CD40L molecules (Morris *et al.*, *J. Biol. Chem.* 274:418, 1999).

The TNF superfamily (TNFSF) consists of an expanding number of proteins

(see Table I) which are crucial for the development and functioning of the immune, hematological, and skeletal systems. TNFSF proteins are ligands for a corresponding set of receptors of the TNF receptor superfamily (TNFRSF). All TNFSF members are expressed as Type II membrane proteins, with the exception of lymphotoxin-alpha which is produced as a secreted protein. However, soluble forms of several TNFSF proteins can be released from the cell surface by proteolytic cleavage, usually by specific metalloproteinases.

The production of soluble forms of TNFSF proteins has been an important step in the study of these proteins. Soluble TNFSF ligands can be used to study the activities of these proteins in vitro without the complexities in interpretation that result when cells or cellular membranes expressing TNFSF proteins are added. In addition, soluble forms of several TNFSF proteins have potential as therapeutic agents for human diseases. In particular, TNF- $\alpha$  has been extensively studied for the treatment of cancer and soluble CD40L is currently undergoing clinical trials to assess its antitumor effects.

To produce soluble forms of TNFSF proteins, either the membrane protein is expressed in a cell line possessing a protease capable of separating the TNFSF extracellular domain from the transmembrane domain or a truncated form of the TNFSF protein is produced which consists solely of the extracellular domain plus a signal sequence. In either case, certain soluble forms of TNFSF proteins are unstable in solution as simple homotrimers composed solely of the extracellular domain. For example, naturally solubilized TNF- $\alpha$  is labile under physiological conditions

[Schuchmann, 1995 #129]. To solve this stability problem, chimeric proteins have been constructed according to one of four different design principles: (1) The extracellular portion of the TNFSF protein has been expressed fused to the dimeric portion of the immunoglobulin Fc fragment US Patent 5,155,027, Oct. 13, 1992, issued to, Andrzej Z. Sledziewski, et al. In the case of CD40L and OX40L, this yields a soluble molecule which is significantly less active than the native membrane form of this protein. (2) The extracellular portion of the TNFSF protein has been expressed with an antigenic tag (usually the FLAG motif) fused to its N-terminus [Mariani, 1996 ]. The addition of an antibody to the tag (e.g., anti-FLAG antibody) aggregates these proteins into a multimeric form. Crosslinking enhances activity on B cells. (3) The extracellular portion of the TNFSF protein has been expressed fused to the spontaneously dimerizing extracellular portion of the CD8 molecule [Hollenbaugh, 1992 ]. In the case of CD40L, this creates a hexameric molecule [Pullen, 1999 ] which is likely formed by two CD40L trimers attached to three CD8 dimeric stalks. Despite this, the addition of an anti-CD8 antibody to crosslink the CD40L-CD8 fusion protein yields a further enhancement of CD40L activity on B cells. (4) The extracellular portion of the TNFSF protein has been expressed fused to a trimerizing isoleucine zipper which maintains the overall trimeric structure of the protein [US Patent 5,716,805, Feb. 10, 1998, issued to Subashini Srinivasan et al. This soluble CD40L trimer or 'sCD40LT' is the form of that protein now being clinically tested in humans for its anti-tumor effects.

Compounding the difficulties in producing stable forms of soluble TNFSF proteins are compromises in bioactivity. As exemplified by FasL, TNF, and CD40L, many of the



soluble forms of these proteins lack the full range of stimulatory activities displayed by the membrane forms of these molecules. For FasL, several groups have reported that naturally produced soluble FasL (generated by proteolytic cleavage from the membrane form) has a spectrum of activities that is distinctly different from the membrane form. Soluble FasL induces apoptosis in activated CD4<sup>+</sup> T cells but not fresh, resting CD4<sup>+</sup> T cells. In contrast, both types of CD4<sup>+</sup> T cells are killed by membrane FasL or a recombinant soluble form of FasL (WX1) that spontaneously aggregates into oligomers larger than a decamer. For TNF, T cell activation through stimulation of TNFR II, the 80 kDa receptor for TNF, is much greater with membrane TNF than soluble TNF. However, if soluble TNF is produced as a tagged protein and crosslinked with an antibody against the tag, then it completely mimics the activities of membrane TNF [Schneider, 1998]. Finally, for CD40L, the stimulatory effects of a soluble form of this TNFSF protein are enhanced by crosslinking [Kehry, 1994] and yields an activity similar to membrane CD40L. For example, soluble CD40L-CD8 fusion protein requires crosslinking with a antibody to CD8 in order to drive resting B cells to proliferate to a degree similar to membrane-bound CD40L. ). Even more strikingly, although membrane-bound CD40L expressed on baculovirus-transduced SF9 insect cells is a strong B cell stimulus, small vesicles (10 - 1,500 nm) prepared from the membranes of these cells are less stimulatory. However, ultracentrifugation of these vesicles creates aggregates which have the full activity of the original membrane CD40L protein. This indicates that B cells are more highly stimulated by a large surface of CD40L than they are by a smaller surface expressing this membrane ligand.

Taken together, the above reports suggest that, for some TNFSF/TNFRSF ligand/receptor pairs at least, it is essential to cluster receptors together for full

signaling activity. By this interpretation, the efficacy of the membrane forms of FasL, TNF, and CD40L occurs because these ligands can move in the plane of the membrane toward the contact zone with a receptor-bearing responding cell, thereby clustering ligated receptors to form a receptor-dense region of the membrane. This interpretation is further supported by experiments where crosslinking of a soluble TNFSF protein effectively mimics the activity of the membrane form of the protein [Scheider, 1998].

In all of the above examples, no more than three amino acid chains have been caused to associate together. There is a need to produce multimeric protein molecules where more than three amino acid chains are caused to associate into a single soluble molecular complex. An important example comes from studies of CD40L (also called CD154 or TNFSF5), which is a member of the TNF family of molecules that are normally expressed as insoluble, cell membrane proteins. It has been shown that soluble homotrimers composed of the extracellular regions of CD40L, TNF, and FasL are not potently active on resting cells that bear receptors for these proteins. However, if these proteins are expressed with a tag on their ends (e.g., the FLAG peptide sequence) and then the trimers are extensively crosslinked using an antibody to FLAG, full activity appears (Schneider *et al.*, *J. Exp. Med.* 187:1205, 1998). From this, it can be inferred that the soluble single-trimer forms of these molecules does not duplicate the multivalent interactions that normally occur when a receptor-bearing cell comes in contact with the membrane of a cell expressing numerous ligand trimers on its surface. This distinction may be due to a need for receptor clustering for full signaling (Bazzoni and Beutler, *N. Engl. J. Med.* 334:1717, 1996), which in turn is only possible with a multimeric ligand engaging many receptors at the same time in a localized region of the

cell membrane.

## SUMMARY OF THE INVENTION

- 5           The present invention contemplates a method of preparing soluble, multimeric mammalian proteins by culturing a host cell transformed or transfected with an expression vector encoding a fusion protein comprising the hub, body, and neck region of a collectin molecule and a heterologous mammalian protein.
- 10           In one embodiment, the heterologous mammalian protein comprises an extra cellular domain of a mammalian transmembrane protein; the resulting fusion protein forms a multimer.
- In another embodiment, the heterologous mammalian protein comprises a
- 15           soluble protein such as a cytokine; the resulting fusion protein forms a multimer.
- In another embodiment, sites of proteolytic degradation are included or removed from the fusion protein; the resulting fusion protein forms a multimer from which are cleaved single units at a rate made variable by the nature of the proteolytic
- 20           digestion sites either included or excluded.
- In yet another embodiment, special attention is given to the immunogenicity of the fusion protein by altering the junction between the two naturally occurring proteins from which it is made; the resulting fusion protein may be less or more able

to elicit an immune response against itself, which could lengthen its persistence or contribute to its immunological effectiveness.

A hybrid nucleotide sequence of no more than 1528 base pairs including a sequence  
5 defining a structural gene expressing a conjoined single strand of a multimeric TNFSF-SPD  
fusion protein, said structural gene having a nucleotide base sequence selected from  
members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5 is  
disclosed by this invention. In one embodiment, the DNA segment the structural gene has a  
sequence expressing a single hybrid amino acid chain of TNFSF-SPD, the segment having a  
10 first SPD nucleotide base sequence of SEQ ID NO 1, from base 32 to base 799, and a second  
sequence, expressing a portion of TNFSF stalk, selected from members of the group  
consisting of SEQ ID NO 1, from base 800 to base 1444, SEQ ID NO 3, from base 800 to  
base 1528, and SEQ ID NO 5, from base 800 to base 1441.

15 In another embodiment, a recombinant DNA molecule has vector operatively linked  
to an exogenous DNA segment defining a structural gene expressing a single amino acid  
chain of TNFSF-SPD. This structural gene has a nucleotide base sequence selected from  
members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5, any  
functional equivalents and modifications thereof. There is also attached an appropriate  
20 promoter for driving the expression of said structural gene in a compatible host organism.  
The organism can be *E. coli*, a yeast, a higher plant or animal.

Yet another embodiment contemplated by the invention is multimeric TNFSF-SPD  
fusion protein having a plurality of polypeptide trimers, a first trimer consisting of peptide

strands of members of the TNF superfamily (TNFSF) of ligands, and a second trimer strand from a collectin molecule, each first trimer conjoined to a second polypeptide trimer strand from a collectin molecule, wherein said ligand strand is substituted for native carbohydrate recognition domains (CRD) of the collectin molecules. The conjoined collectin strands are covalently bound in parallel to each other, forming a multimeric fusion protein comprising a plurality of trimeric hybrid polypeptide strands radiating from a covalently bound center hub of the molecule. The free end of each trimeric radiating strand has a TNFSF moiety attached. The TNFSF moiety is one selected from the group consisting of ligands LTA, TNF, LTB, and TNFSF4 to TNFSF 18 as shown in Table II, and their functional equivalents, and modifications thereof.

The invention also contemplates a method for preparing a CD40-SPD multimeric fusion polypeptide, including the steps of initiating a culture, in a nutrient medium, of procaryotic or eucaryotic host cells transformed with a recombinant DNA molecule including an expression vector, appropriate for the cells, operatively linked to an exogenous DNA segment defining a structural gene for CD40-SPD ligand. The structural gene has a nucleotide base sequence of SEQ ID NO 1 from about base 32 to about base 1444. Thereafter, the culture is maintained for a time period sufficient for the cells to express the multimeric molecule.

Also contemplated is a method of producing a secreted, very large, biologically active, multimeric tumor necrosis factor superfamily ligand fusion protein chimera that is highly immunogenic and not readily diffusable. The steps for this method are as follows:

1. introducing into a host cell a first chimeric DNA construct including a

transcriptional promoter operatively linked to a first secretory signal sequence, followed downstream by, and in proper reading frame with a first DNA sequence encoding a polypeptide chain of a first TNFSF ligand requiring multimerization for biological activity. This sequence is joined to a second DNA sequence encoding a collectin polypeptide at the site where the collectin's CRD was purposefully removed.

2. introducing into the host cell, a second DNA construct including a transcriptional promoter operably linked to a second secretory signal sequence followed downstream by, and in proper reading frame with, a third DNA sequence encoding a second polypeptide chain of a second TNFSF ligand, joined to a fourth DNA sequence encoding a collectin polypeptide, wherein the collectin's CRD was purposefully removed, and then,

3. growing the host cell in an appropriate growth medium under physiological conditions to allow the secretion of a large multimerized polypeptide fusion protein, wherein the first polypeptide chain of a TNFSF-SPD protein is bound by parallel bonding of the respective collectin domain trimer to the second polypeptide chain of a different TNFSF-SPD polypeptide trimer, and wherein the multimerized polypeptide fusion protein exhibits biological activity characteristic of both membrane-attached TNFSFs, and

4. isolating the biologically active, multimerized TNFSF-SPD polypeptide fusion from said host cell. The chimeric reactant compounds are humanized to guard against destruction by a potential human recipient's immune system.

A final method of preparing a multimeric TNFSF-SPD ligand fusion protein contemplated requires a) preparing a first DNA segment coding for a strand of an exposed extracellular portion of TNFSF; b) preparing a second DNA segment coding for a collectin polypeptide strand, wherein the collectin's CRD domain of the strand has been removed; c)

conjoining the first and second DNAs in proper reading frame, thereby creating a TNFSF-collectin DNA construct; d) inserting the construct into an expression vector system; e) introducing the vector system into an appropriate cell in culture under suitable conditions; f) harvesting and purifying spent medium from the culture; and finally g) assaying for presence  
5 of multimeric TNFSF-collectin fusion protein.

A method for stimulating the immune response in potentially immunocompetent cells using multimeric TNFSF fusion proteins by contacting the cells with the multimeric TNFSF fusion proteins, causing the cells to proliferate, is also contemplated. The cells used  
10 may be resting B cells. There is also a method for increasing antigenicity of cells by contacting the cells with the multimeric TNFSF fusion proteins. In this case, the cells may be tumor cells or HIV positive cells.

Other preferred embodiments contemplate the methods of preparation  
15 described above, wherein the host transformed is either a prokaryote, such as E. coli, a eukaryote, for example yeast, such as S. cerevisiae, or a higher plant, such as alfalfa or tobacco.

Still further embodiments and advantages of the invention will become  
20 apparent to those skilled in the art upon reading the entire disclosure contained herein.

## BRIEF DESCRIPTION OF THE DRAWINGS

**Figure 1. Structure of the CD40L-SPD fusion protein.** The extracellular portion of the CD40L homotrimer, including its membrane-proximal stalk, was fused to the body of SPD.

5 The N-terminus of SPD contains two cysteines which link the homopolymer together by disulfide bonds forming a hub. The trimeric collagenous stalk extend from the hub as a cruciate structure and end in a spontaneously trimerizing neck region. The amino acid domains in a single chain of the CD40L-SPD are shown at the top. At the bottom is the tetrameric (four CD40L trimers) which is expected to form. In addition, the hub region of  
10 SPD can participate in stacking up to 8 or more cruciate forms into higher order aggregates.

**Figure 2. Ion-exchange chromatography of murine CD40L-SPD.** CHO cells expressing murine CD40L-SPD were grown in serum-free media, concentrated using a 100 kDa cutoff ultrafiltration membrane, and diafiltered into 50 mM bicine, pH 9.0, 1 mM EDTA. Using an  
15 FPLC system, the protein from 400 mL of media was applied to a Fractogel  $\text{SO}_3^-$  650M column and eluted with a linear salt gradient. 3 mL samples were collected. Shown are curves for protein concentration ( $\text{OD}_{280}$ ), conductivity as % 1 M NaCl in the buffer, and ELISA-detectable CD40L-SPD assayed at 1:100 dilution.

20 **Figure 3. Size fractionation of murine CD40L-SPD by ultrafiltration.** CD40L-SPD is a 471 amino acid protein with a predicted molecular weight of 49,012 for each of the twelve component chains in the dodecamer (composed of four trimeric subunits). This does not include added carbohydrates. Therefore, the full dodecamer will have a molecular weight in excess of 600,000. However, from the literature on recombinant surfactant protein D made



in CHO cells, it appears that some of the product will be in the form of trimers that are not part of a cruciate-formed dodecamer. To determine what percentage of CD40L-SPD was produced in a multimeric form, supernatant from the transfected CHO cells were passed through filters of different porosities (rated for their ability to retard globular proteins). An ELISA was used to detect the amount of CD40L-SPD (measured at multiple dilutions) that passed through the filter. As shown, about 90% of the protein is retained by a 300,000 kDa cut-off filter. This indicates that most of the protein is in the dodecameric form. In addition, the cruciate dodecamers of surfactant protein D can also stack on top of each other into even higher molecular weight forms. This is the likely explanation for the small fraction of CD40L-SPD that is retained by the 1,000 kDa cut-off filter.

**Figure 4. Activation of human B cells by human CD40L-SPD.** Conditioned media from CHO cells expressing human CD40L-SPD was added to human B cells along with IL-4. In the left panel, the cells were stained with CyChrome-labeled anti-CD19 to identify B cells and PE-labeled anti-CD3 to identify T cells. As shown, most of the cells proliferating in the culture were CD19<sup>+</sup> CD3<sup>-</sup> B cells. In the right panel, the cells were stained with CyChrome-labeled anti-CD19 to identify B cells and PE-labeled anti-CD80 (B7-1) to identify this co-stimulatory molecule. As shown, almost all of the B cells were induced by CD40L-SPD to express CD80.

**Figure 5. Activation of murine B cells by murine CD40L-SPD.** Murine CD40L-SPD was added to resting murine splenic B cells for a two day culture period. For the final 4 hours, the cultures were pulsed with <sup>3</sup>H-thymidine, following which the cells were harvested and DNA synthesis was measured by scintillation counting. As shown, CD40L-SPD is

nearly as effective as anti-IgM in promoting the proliferation of resting B cells.

**Figure 6. CD40L-SPD stimulation of macrophage chemokine production.** Conditioned media from CHO cells expressing human CD40L-SPD, an inactive mutant of human CD40L-SPD (T147N-CD40L-SPD), or murine CD40L-SPD (mCD40L-SPD) were added to cultures of human monocyte-derived macrophages. As a negative control, this media was heat-inactivated at 60 °C for 30 minutes. Also shown is a form of soluble CD40L (sCD40L) consisting of 149 amino acids from the extracellular domain of human CD40L (Peprotech) added at 1 µg/mL. 24 hours later, supernatants were collected and assay for MIP-1 $\beta$  by ELISA (R & D Systems). The weak activity of soluble single-trimer CD40L (sCD40L) is apparent. In contrast, native human and murine CD40L-SPD strongly activated the macrophages to produce MIP-1 $\beta$ . In contrast, heat-inactivated CD40L-SPD was inactive. As expected, the inactive mutant, T147N-CD40L-SPD, also failed to stimulate macrophages, demonstrating that the CD40L portion and not the SPD portion of the protein was responsible for stimulating the macrophages.

**Figure 7. Expression of RANKL/TRAPE-SPD production from CHO cells detected by ELISA.** Antibodies against RANKL/TRAPE were used to construct an ELISA capable of detecting the RANKL/TRAPE protein. As shown, there was no background with the media control. Using a fusion protein between CD70 (CD27L or TNFSF7) and SPD, there was also no signal, indicating the specificity of the ELISA. However, using CHO cells transfected with an expression plasmid for CD70-SPD, immunoreactive secreted protein was clearly detectable. This demonstrates the generalizability of the method for expressing TNFSF members as fusion proteins with collectins such as SPD.

## DESCRIPTION OF THE PREFERRED EMBODIMENT

### 1. Definition of Terms

**Multimeric:** As used herein the term multimeric refers to a multimer of a  
5 polypeptide that is itself a trimer (i.e., a plurality of trimers).

**Functional Equivalent:** Herein refers to a sequence of a peptide or  
polypeptide that has substantial structural similarity and functional similarity to  
another such sequence.

**Modifications:** Herein refers to point changes involving single amino acids,  
10 wherein the functionality is altered, without appreciably altering the primary  
sequence or primary structure of a peptide or polypeptide.

**Amino Acid:** All amino acid residues identified herein are in the natural L-  
configuration. In keeping with standard polypeptide nomenclature, J. Biol. Chem.,  
243:3557-59, (1969), abbreviations for amino acid residues are as shown in the  
15 following Table of Correspondence:

# TABLE OF CORRESPONDENCE

<u>SYMBOL</u>		<u>AMINO ACID</u>
<u>1-Letter</u>	<u>3-Letter</u>	
5		
Y	Tyr	L-tyrosine
G	Gly	glycine
F	Phe	L-phenylalanine
M	Met	L-methionine
10	A	L-alanine
S	Ser	L-serine
L	Ile	L-isoleucine
L	Leu	L-leucine
T	Thr	L-threonine
15	V	L-valine
P	Pro	L-proline
K	Lys	L-lysine
H	His	L-histidine
Q	Gln	L-glutamine
20	E	L-glutamic acid
W	Trp	L-tryptophan
R	Arg	L-arginine
D	Asp	L-aspartic acid
N	Asn	L-asparagin
25	C	L-cysteine

It should be noted that all amino acid residue sequences are represented herein by formulae whose left to right orientation is in the conventional direction of amino-terminus to carboxy-terminus. Furthermore, it should be noted that a dash at the beginning or end of an amino acid residue sequence indicates a bond to a radical such as H and OH (hydrogen and hydroxyl) at the amino- and carboxy-termini, respectively, or a further sequence of one or more amino acid residues up to a total of

about fifty residues in the polypeptide chain.

**Base Pair (bp):** A partnership of adenine (A) with thymine (T), or of cytosine (C) with guanine (G) in a double stranded DNA molecule.

**Constitutive promoter:** A promoter where the rate of RNA polymerase binding and initiation is approximately constant and relatively independent of external stimuli. Examples of constitutive promoters include the cauliflower mosaic virus 35S and 19S promoters described by Poszkowski et al., *EMBO J.*, 3:2719 (1989) and Odell et al., *Nature*, 313:810 (1985).

**DNA:** Desoxyribonucleic acid.

**Enzyme:** A protein, polypeptide, peptide RNA molecule, or multimeric protein capable of accelerating or producing by catalytic action some change in a substrate for which it is often specific.

**Expression vector:** A DNA sequence that forms control elements that regulate expression of structural genes when operatively linked to those genes.

**Expression:** The combination of intracellular processes, including transcription and translation undergone by a structural gene to produce a polypeptide.

**Insert:** A DNA sequence foreign to the rDNA, consisting of a structural gene and optionally additional DNA sequences.

**Nucleotide:** A monomeric unit of DNA or RNA consisting of a sugar moiety (pentose), a phosphate, and a nitrogenous heterocyclic base. The base is linked to the sugar moiety via the glycosidic carbon (1' carbon of the pentose) and that combination of base and sugar is a nucleoside. When the nucleoside contains a phosphate group bonded to the 3' or 5' position of the pentose it is referred to as a nucleotide.

**Operatively linked or inserted:** A structural gene is covalently bonded in correct reading frame to another DNA (or RNA as appropriate) segment, such as to an expression vector so that the structural gene is under the control of the expression vector.

5        **Polypeptide and peptide:** A linear series of amino acid residues connected one to the other by peptide bonds between the alpha-amino and carboxy groups of adjacent residues.

10        **Promoter:** A recognition site on a DNA sequence or group of DNA sequences that provide an expression control element for a gene and to which RNA polymerase specifically binds and initiates RNA synthesis (transcription) of that gene.

15        **Inducible promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated by external stimuli. Such stimuli include light, heat, anaerobic stress, alteration in nutrient conditions, presence or absence of a metabolite, presence of a ligand, microbial attack, wounding and the like.

**Spatially regulated promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated in a specific structure of the organism such as the leaf, stem or root. Examples of spatially regulated promoters are given in Chua et al., *Science*, 244:174-181 (1989).

20        **Spatiotemporally regulated promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated in a specific structure of the organism at a specific time during development. A typical spatiotemporally regulated promoter is the EPSP synthase-35S promoter described by Chua et al., *Science*, 244:174-181 (1989).

**Temporally regulated promoter:** A promoter where the rate of RNA polymerase binding and initiation is modulated at a specific time during development. Examples of temporally regulated promoters are given in Chua et al., *Science*, 244:174-181 (1989).

5       **Protein:** A linear series of greater than about 50 amino acid residues connected one to the other as in a polypeptide.

**Recombinant DNA molecule:** A hybrid DNA sequence comprising at least two nucleotide sequences not normally found together in nature.

**RNA:** Ribonucleic acid.

10       **Selective Genetic marker:** A DNA sequence coding for a phenotypical trait by means of which transformed cells can be selected from untransformed cells.

**Structural gene:** A DNA sequence that is expressed as a polypeptide, i.e., an amino acid residue sequence.

15       **Synthetic promoter:** A promoter that was chemically synthesized rather than biologically derived. Usually synthetic promoters incorporate sequence changes that optimize the efficiency of RNA polymerase initiation.

## 2.    Introduction

20       This invention discloses the production of TNFSF proteins as multimeric (i.e., many trimers) ligands fused onto a trimeric, branched protein backbone. Collectin molecules are ideal for this purpose because they are formed from many trimeric, collagenous arms linked to a central hub by disulfide bonds. Of the collectins, pulmonary surfactant protein D (SPD) was chosen initially because it is a homopolymer encoded by a single gene, unlike C1q and surfactant protein A, which are composed of two different protein subunits. In addition,

recombinant SPD has been successfully expressed *in vitro* in reasonable yield [Crouch, 1994], and a peptide containing the “neck” region of SPD was shown to spontaneously trimerize in solution [Hoppe, 1994]. Consequently, extracellular domains of human and murine CD40L were substituted for the carbohydrate recognition domain of pulmonary surfactant D (SPD) to create a four-armed molecule (three peptide chains per arm) with CD40L at the end of each arm. This molecule is named CD40L-SPD. In addition, because SPD tends to stack into higher order aggregates with up to 8 molecules associated at the hub [Crouch], even greater degree of multimerization can occur [Lu, 1993]. CD40L-SPD therefore mimics the expression of CD40L by an activated T cell in that it presents a multivalent complex similar to membrane-bound CD40L. While remaining soluble, CD40L-SPD equals membrane CD40L in its range of activities.

### 3. Construction of expression plasmids for CD40L-SPD.

cDNAs of exposed human and murine CD40L, removed from cell membranes, were cloned by PCR by well-known methods. Murine surfactant protein D was cloned by hemi-nested PCR from murine lung mRNA (Clontech). cDNA was prepared using Superscript II reverse transcriptase (Life Technologies, Gaithersburg, MD) and random hexamers as primers. PCR primer sequences were as follows (the underlined bases indicate restriction endonuclease sites for cloning into the vector):



- mSPD5: 5'-CTGACATGCTGCCCTTTCTCTCCATGC-3'
- mSPD3ext: 5'-GGAGGCCAGCTGTCTCCAGCCTGTTTGC-3'
- rmSPD5: 5'-GGGG'CTAGC**GAATTCCACCAGGAAGCAAT**CTGACATGCTGCCCTTT-  
CTCTCCATGC-3'
- 5 CD40L/SPD3: 5'-TCTATCTTGTCCAACCTTCTATG/GCCATCAGGGAACAATGCAGCTTTC-3'
- SPD/CD40L5: 5'-AAAGCTGCATTGTTCCCTGATGGC/CATAGAAGGTTGGACAAGATAGAAG-3'
- CD40L3: 5'-GGGCTCGAGGTACCAGTTCTACATGCCTTGGAGTGATAAT-3'
- SPD/mCD40L5: 5'-GAAAGCTGCATTGTTCCCTGATGGC/CATAGAAGATTGGATAAGGTCTGAAG-3'
- mCD40L/SPD3: 5'-CTTCGACCTTATCCAATCTTCTATG/GCCATCAGGGAACAATGCAGCTTTC-3'
- 10 mCD40L3: 5'-GGGGGGTACCCTGCTGCAGCCTAGGACAGCGCAC-3'

Because the murine SPD sequence of the 5' untranslated region containing the ribosomal binding site was unknown when this work was started [Motwani, 1995], a primer (rmSPD5) was designed based on the available rat sequence [Shimizu, 1992] which extended the 5' end with rat sequence (shown in bold) along  
15 with an added Nhe I site (underlined).

#### 4. Creation of the CD40L-SPD Fusions.

To create the CD40L-SPD fusions, overlap PCR was used. Murine SPD was amplified by nested PCR using mSPD5 and mSPD3ext for the first round of 30  
20 cycles. The product was diluted 1:1,000 and 1 µL was amplified for another 30 cycles using rmSPD5 and CD40L/SPD3, where the 3' half of CD40L/SPD3 is a reverse primer for SPD C-terminal to the neck region (deleting the CRD) and the 5' half of CD40L/SPD3 contains bases from the N-terminus of the extracellular portion of CD40L (immediately adjacent to the transmembrane region). Similarly, the  
25 CD40L plasmid was amplified with SPD/CD40L5 and CD40L3, which contains a

Kpn I site (underlined). All of these PCRs were performed with Pfu cloned polymerase (Stratagene,) using hot start (Ampliwax, Perkin-Elmer) and the thermocycling program: 94 °C for 2.5 min; then 30 cycles of 94 °C for 10 sec, 43 °C for 30 sec, and 75 °C for 7 min.

5

To form the chimeric construct, 1 µL of a 1:1,000 dilution of gel-purified products from the above reactions was combined and amplified with rmSPD5 and CD40L3. Because Pfu polymerase did not consistently yield the expected 1.62 kb overlap product, AccuTaq LA DNA polymerase (Sigma) was used for this PCR, using the thermocycling program: 94 °C for 2.5 min; then 30 cycles of 98 °C for 20 sec, 43 °C for 30 sec, and 68 °C for 10 min. The resulting product was digested with Nhe I and Kpn I, gel-purified, and ligated into the Nhe I and Kpn I sites in the expression plasmid, pcDNA3.1(+) (Invitrogen, Carlsbad, CA). DH5 E. coli were transformed with the construct and plasmid DNA was purified either by double banding in ethidium bromide-CsCl gradients or by anion exchange resin (QIAGEN). To form the T147N-CD40L-SPD construct, the same approach was used except that the CD40L coding region was taken from the expression plasmid for T147N-CD40L [Kornbluth]. The amino acid sequence at the junction between SPD and CD40L is ...KAALFPDG/HRRLDKIE..., where the C-terminal portion begins the sequence for CD40L. To form mCD40L-SPD, a similar approach was taken except that primers SPD/mCD40L5, mCD40L/SPD3, and mCD40L3 were used for amplifications involving murine CD40L sequences. The amino acid sequence at the junction between SPD and murine CD40L is ...KAALFPDG/HRRLDKVE..., where the C-terminal portion begins the sequence for murine CD40L. Both DNA strands of each construct were sequenced to confirm that the constructs were correct. In other experiments, an entirely humanized construct, consisting of human CD40L fused to

human SPD, was constructed (data not shown).

## 5. Construction of expression plasmid for murine RANKL/TRANCE (TNFSF 11).

Spleen cells from C3H/HeJ mice were stimulated with 5 µg/ml concanavalin A and 10 ng/ml IL-2 (Sigma) for 8 hours (31). mRNA was isolated using the Micro FastTrack kit (Invitrogen). cDNA was prepared using Superscript II reverse transcriptase (Life Technologies) and random hexamers as primers. PCR primer sequences were as follows (where the underlined bases indicate restriction endonuclease sites for cloning into the vector):

10	5mRANKL-ext:	5'-CATGTTCTGCGCCCTCTC-3'
	3mRANKL-ext:	5'-GTACAGGCTCAAGAGAGAGGGC-3'
	5mRANKL-int:	5'-ATACTCGAGCGCAGATGGATCCTAAC-3'
	3mRANKL-int:	5'-GGGGTTTAGCGGCCGCTAATGTTCCACGAAATGAGTTC-3'

15 The extracellular portion of RANKL/TRANCE was cloned by nested PCR. In the first round of PCR, 5mRANKL-ext and 3mRANKL-ext were used with Pfu cloned polymerase (Stragene) using the thermocycling program: 94 °C for 2.5 min; then 30 cycles of 94 °C for 10 sec, 50 °C for 30 sec, and 75 °C for 2 min. The product was diluted 1:1,000 and 1 µL was amplified for another 30 cycles using 5mRANKL-int and 3mRANK-int, 20 which contain an Xho I site and a Not I site respectively. The resulting product was digested with Xho I, blunt-ended with T4 DNA polymerase, then digested with Not I and gel-purified. The CD40L-SPD expression plasmid described above was digested with Msc I and Not I and gel purified. Then the RANKL/TRANCE sequence was ligated into this vector in frame with the SPD coding sequence. The amino acid sequence at the junction between 25 SPD and RANKL/TRANCE is ...KAALFPDG/RAQMDPNR..., where the N-terminal portion is from SPD and the C-terminal portion is the extracellular sequence of

RANKL/TRANCE. Both DNA strands of each construct were sequenced to confirm that the constructs were correct.

#### 6. Stable transfection of DHFR-deficient CHO cells and amplification.

DG44 (a line of CHO-K1 cells deficient in dihydrofolate reductase (DHFR)) (32) and pCH1P (a plasmid containing the hamster DHFR minigene) (33) were gifts from Dr. Lawrence Chasin, Columbia University, New York, NY . DG44 cells were cultured in  $\alpha$ -MEM consisting of ribo- and deoxynucleoside-free  $\alpha$ -MEM (BioWhittaker, Walkersville, MD) supplemented with 200  $\mu$ M L-glutamine, 10% fetal bovine serum (FBS) and 10  $\mu$ g/ml each of adenosine, deoxyadenosine, and thymidine (Sigma). All cell cultures described were negative in a mycoplasma rRNA assay (Gen-Probe, San Diego). DG44 cells in six-well plates were transfected by the method of Okayama and Chen ((34) with 10  $\mu$ g of expression plasmid and 0.05  $\mu$ g of pCH1P (200:1 ratio). After two days, the transfected DG44 were trypsinized and transferred to 100 mm plates. At this point, the media was switched to  $\alpha$ <sup>-</sup>-MEM which differs from  $\alpha$ -MEM in that dialyzed FBS (HyClone Systems, Logan, UT) was used and no nucleoside supplements were added. Only cells containing the DHFR minigene were able to grow in  $\alpha$ <sup>-</sup>-MEM, and colonies were selected after 10 days, cloned using cloning rings, and transferred to 12.5 cm<sup>2</sup> flasks. Clones were selected for expansion using an ELISA to screen for the production of either murine or human CD40L (see below). Using the method described by Kingston *et al.* (35), escalating doses of methotrexate were used to amplify the transfected genes over a period of 6-14 months until the cells grew well in 80  $\mu$ M methotrexate. Each expressing clone was re-cloned once or twice more in order to select the highest expressing cells.

#### 7. Preparation of human and murine CD40L-SPD in serum-free media.

Selected clones were adapted for growth in nucleoside-free UltraCHO media

(BioWhittaker) supplemented with 50-100 µg/mL ascorbic acid and 50 µM methotrexate (Sigma). The non-adherent population was further adapted for suspension growth in roller bottles. In some experiments, the cells were adapted from  $\alpha$ -MEM to CHO-S-SFM II media (Life Technologies) supplemented with  
5 ascorbic acid and 50 µg/mL L-proline.

#### **8. ELISA assay for human and murine CD40L-SPD.**

To assay for correctly folded CD40L, wells of a MaxiSorb 96-well plate (Nunc) were coated overnight at 4 °C with 50 µL of carbonate-bicarbonate, pH 9.40  
10 buffer containing 0.5 µg/mL 24-31 anti-human CD40L MAb (Ancell) or MR1 anti-murine MAb (Bioexpress, Lebanon, NH). Wells were blocked with 3% bovine serum albumin (BSA) in PBS. 100 µL samples were added to the wells either neat or diluted in a dilution buffer consisting of 1% BSA, 0.9 % NaCl, 50 mM Tris pH 7.40, and 0.1% peroxide-free Tween 20 (Sigma). After shaking for 2 h at 600 RPM,  
15 a plate washer was used to wash the plate four times with 0.9 % NaCl, 50 mM Tris pH 7.40, and 0.1% peroxide-free Tween 20. Then, 100 µL of diluent buffer containing 1 µg/mL biotinylated 24-31 anti-human CD40L Mab (Ancell) or MR1 anti-murine CD40L Mab (Pharmingen, San Diego, CA) was added to each well and again shaken for 2 h. Following another four washes, 100 µL of diluent buffer  
20 containing 1 µg/mL of streptavidin-alkaline phosphatase (Jackson) was added to each well and the plate was shaken for 1 hour. Lastly, after another four washes, color was developed for 10-20 min using 100 µL/well of BluePhos (Kierkegaard & Perry), stop solution was added, and the wells were read at 650 nm in a plate reader.

#### **9. Purification of human and murine CD40L-SPD.**

25 Conditioned UltraCHO media was filtered using a 0.2 µ PES filter unit (Nalgene) and stored at 4 °C for up to 3 months. A preliminary size fractionation

was performed by ultrafiltration through a 100 kDa-cutoff 76 mm membrane (YM-100, Millipore) in a 400 mL stirred cell at 10 lbs/sq. inch pressure of argon. Media was concentrated to about 10 mL, diluted to 100 mL with buffer, and again concentrated to 10 mL for a total of 3 cycles of ultrafiltration and buffer exchange.

5 Buffer was 50 mM Bicine (Calbiochem), adjusted to pH 9.0 with NaOH (about 32 mM Na), and 1 mM EDTA to prevent the activity of any metalloproteinase. Using FPLC equipment (Amersham-Pharmacia), the concentrate was filtered through a 0.45  $\mu$  filter, placed into a 10 mL superloop, applied to a 10 X 30 mm column (HR10/30, Amersham-Pharmacia) packed with Fractogel  $\text{SO}_3^-$  650M (EM  
10 Biosciences), and eluted at 0.5 mL/min at 4 °C with a linear gradient of 0-500 mM NaCl in buffer. As described by the manufacturer, the resolution of proteins on Fractogel  $\text{SO}_3^-$  is enhanced by using a long, thin column geometry. Fractions were collected and screened for human or murine CD40L by ELISA. Positive fractions were pooled, concentrated by ultrafiltration (CentriPrep-30, Millipore), filtered  
15 through a 0.45  $\mu$  filter, and applied to a Superose 6 column (Amersham-Pharmacia) in phosphate-buffered saline.

#### **10. Murine B cell cultures.**

C3H/HeJ mice were euthanized by  $\text{CO}_2$  inhalation under a protocol approved by the  
20 Animal Subjects Committee of the San Diego VA Healthcare System. Splenocytes were isolated by centrifugation over Lympholyte-M (Accurate Chemical & Scientific Corp., Westbury, NY) and B cells were isolated by negative selection using anti-CD43 immunomagnetic beads (Miltenyi Biotec Inc., Auburn, CA). The resting B cells were suspended in Dulbecco's MEM with 10% FBS at a concentration of  $1 \times 10^6/\text{mL}$ , and 100  
25  $\mu\text{L}$  was added to the wells of 96-well flat-bottomed plates. 100  $\mu\text{L}$  of dilutions of murine CD40L-SPD in media or media alone were added to the wells, which were incubated in

8.5% CO<sub>2</sub> at 37 °C for 48 hours. Then, 0.5 µCi/well of <sup>3</sup>H-thymidine was added to each well, and the cells were collected 4 h later onto glass fiber filters using an automated cell harvester. A scintillation counter was used to determine the incorporated radioactivity.

5    **11.    Human B cell cultures.**

Venous blood from consenting subjects was used as a source of human B cells under a protocol approved by the UCSD Institutional Review Board. Blood was collected into syringes containing 5 U/mL heparin and peripheral blood mononuclear cells (PBMC) were isolated by centrifugation over Ficoll-hypaque. The cells were suspended at 2 X 10<sup>5</sup>/mL in  
10    RPMI 1640 containing 200 µM L-glutamine, 10% FBS, 0.832 µM cyclosporin A (Sigma), and 25 ng/mL human IL-4 (R & D Systems) and incubated in 5% CO<sub>2</sub> at 37 °C as described by Schultze *et al.* (36). At intervals, the cells were stained with CyChrome-conjugated anti-CD19 and PE-conjugated anti-CD80 (B7-1) monoclonal antibodies (Pharmingen) and analyzed by flow cytometry.

15

**12.    Human monocyte-derived macrophage and dendritic cell cultures.**

As previously described [Kornbluth], monocytes were isolated from PBMC by adherence to fibronectin-coated plates, plated into 48-well plates, and then cultured in RPMI1640 containing 200 µM L-glutamine and 10% autologous serum  
20    for 7-10 days. Monolayers of the matured cells (about 2 X 10<sup>5</sup>/well), termed monocyte-derived macrophages or MDM, were then washed in media and cultured in 1 mL/well RPMI1640 containing 200 µM L-glutamine and 10% heat-inactivated FBS. Alternatively, dendritic cells (DC) were formed from monocytes by adding GM-CSF and IL-4 to the culture media, and the resulting DC were used 6 days later.  
25    Preparations of CD40L-SPD were added to the wells as indicated. As a positive control, 100 ng/mL bacterial lipopolysaccharide (LPS) from E. coli 0111:B4

(Calbiochem) was added. Supernatants were collected 24 h later and analyzed for cytokine content using ELISA (R & D Systems).

### Example 1.

#### 5    **Design principles in constructing collectin-TNFSF member fusion proteins.**

To express CD40L and other TNFSF members as stable, multimeric proteins, the coding region of the extracellular, C-terminal portion of CD40L was joined in-frame to the collectin, surfactant protein D (SPD). The N-terminus of SPD contains two cysteines which form the disulfide bonds necessary for the 4-armed cruciate  
10    structure of the overall molecule [Brown-Augsburger, 1996 #506]. C-terminal to these cysteines in SPD is a long triple-helical collagenous “stalk” which ends in the “neck” region that promotes the trimerization of each arm of the structure. Immediately after this neck region, the coding sequence for the extracellular portion of CD40L was added, in place of the carbohydrate recognition domain (CRD) of  
15    SPD. The collectins were chosen as the framework for the multimeric construct because of their multi-subunit structure and the trimeric nature of their stalk regions. Appropriateness of replacing the CRD of a collectin with the extracellular region of a TNFSF member is further supported by structural studies of the two protein families. An analysis of the CRD crystal structure of another collectin, ACRP30, indicated  
20    that it was structurally superimposable upon the crystal structures of the extracellular regions of CD40L, TNF, and Fas [Shapiro, 1998]. The successful expression of the collectin-TNFSF fusion protein, CD40L-SPD, indicates that other TNFSF members (Table I) could be conjoined to SPD in a similar manner and that other collectins besides SPD (Table II) could be used as a protein framework instead of SPD.  
25    Because these molecules are formed entirely from naturally occurring proteins, the production of an immune response (e.g., antibodies) to these fusion proteins is



minimized. By deleting portions of the stalk region of the TNFSF proteins, additional constructs can be made which may be even less immunogenic.

## **Example 2.**

### **5 Expression of human and murine CD40L-SPD in CHO cells.**

The coding regions for the extracellular portion of human CD40L, human T147N-CD40L, an inactive mutant of CD40L, or murine CD40L were joined to the neck region of murine SPD, replacing the SPD CRD (Fig. 1). A CMV-driven expression plasmid for the construct was co-transfected with a DHFR minigene into  
10 DNFR-deficient CHO cells. Following selection in nucleoside-free media, expressing CHO clones were amplified by culture in ascending doses of methotrexate. The resulting clones produced about 1-10 µg/mL of the fusion protein over a 3 day period in media containing FBS.

15 Clones were adapted for growth as suspension cells in two types of serum-free media. Murine CHO-SPD produced in UltraCHO (BioWhittaker) was largely retained (about 60% as determined by ELISA) by a 1,000 kDa cutoff ultrafiltration membrane (Pall Corp., Port Washington, NY), consistent with a large multimeric complex formed by the stacking of the SPD portion of the molecule. However, in  
20 CHO-S-SFM II (Life Technologies), nearly all ELISA-detectable murine CHO-SPD passed through a 100 kDa cutoff ultrafiltration membrane (Millipore), suggesting that the protein was either folding incorrectly in this media or was being degraded by proteolysis. Consequently, the purification method was optimized for the spent UltraCHO media.

25

### Example 3.

#### Purification of human and murine CD40L-SPD.

Purification procedures were developed for murine CD40L-SPD, but the same methods could be applied to human CD40L-SPD with minor modifications.

5 Murine CD40L-SPD has a predicted m.w. of 49 kDa per chain, or about 600 kDa per 12-chain, cruciate molecule, the amino acid sequence predicts a pI of 9.10.

Accordingly, conditioned media was concentrated by ultrafiltration through a 100 kDa cutoff filter, which also fractionates the sample on a size basis. After diafiltration into 50 mM bicine, pH 9.00 (also containing 1 mM EDTA added to  
10 inhibit metalloproteinases), the sample was applied to a variety of cationic exchange resins. Using Source 30S (Amersham-Pharmacia), most of the ELISA-detectable protein did not bind and was recovered in the flow-through. However, as reported by Morris et al. {Morris}, Fractogel SO<sub>3</sub> 650M retained the protein. The retention by this tentacular resin and not by Source 30S suggests binding to positively charged  
15 residues that are not on the protein surface. Using a linear NaCl gradient, ELISA-detectable protein elutes at between 0.15-0.30 M NaCl under these conditions (Fig. 2). In selected experiments, the protein was further purified using a Superose 6 sizing column. Most of the ELISA-detectable protein eluted in the excluded volume, indicating an apparent m.w. of greater than 1,000 kDa (Fig. 3).

20

### Example 4.

#### Activity of CD40L-SPD on human B cells.

Schultze *et al.* described a system using CD40L-expressing cells plus IL-4 and cyclosporin A (to inhibit T cell growth) as a means to grow very large numbers of B cells  
25 from a small sample of blood. Because CD40L activates these B cells to express high levels of B7 molecules (CD80 and CD86), the proliferating B cells were effective in presenting

peptide antigens and rival non-dividing dendritic cells as antigen-presenting cells (APCs) (36). To determine if the CD40L-SPD fusion protein could replace CD40L-expressing cells in this system, PBMC were cultured with CD40L-SPD in addition to IL-4 and cyclosporin A. Under these conditions the cells grew to saturation density every three days. After three weeks, the cultures were almost entirely CD19<sup>+</sup> B cells which express high levels of CD80 (Fig. 4). This indicates that CD40L-SPD can be used in *ex vivo* systems where a soluble yet effective form of CD40L is needed to stimulate cells for immunotherapeutic applications.

#### Example 5.

##### 10 Activity of CD40L-SPD on murine B cells.

Resting murine B cells are particularly difficult to stimulate with most soluble forms of CD40L. Even with murine CD40L-CD8 fusion proteins, it is necessary to crosslink the protein with antibodies against CD8 in order to achieve maximal proliferation in culture [Klauss, 1999]. Accordingly, resting murine B cells were negatively selected with immunomagnetic beads. As shown in Fig. 5, murine CD40L-SPD was as effective as anti-IgM antibody in driving B cells to proliferate. This indicates that CD40L-SPD can mimic the multivalent interactions that occur when a responding cell comes in contact with CD40L-bearing activating cells.

##### 20 Example 6.

##### Activity of CD40L-SPD on human macrophages and dendritic cells.

CD40L is a powerful stimulant for macrophages (reviewed in (28)) and dendritic cells (40). Accordingly, preparations of CD40L-SPD were added to monocyte-derived macrophages and the production of MIP-1 $\alpha$  was used as a measure of stimulation. As shown in Fig. 6, both human and murine CD40L-SPD were able to stimulate macrophages, whereas the T147N-CD40L-SPD mutant was inactive as expected.

## DISCUSSION

These examples define a new method of producing multimeric (i.e., many trimers) of CD40L as a fusion protein with SPD. Also prepared and expressed were  
5 similar fusion proteins between murine RANKL/TRANCE (TNFSF11) or murine CD27L/CD70 (TNFSF7) joined to murine SPD (data not shown). This suggests that virtually all TNFSF members could be successfully produced as fusion proteins with SPD. Furthermore, it is also likely that other collectins besides SPD could be used in these fusions, given the strong structural homologies between the CRDs of the  
10 collectins and the extracellular domains of TNFSF members [Shapiro] which can be substituted for these CRDs. Given the 17 known TNFSF members and 9 known collectins, at least 153 fusion protein combinations are possible.

SPD was selected for initially because it is a soluble homopolymer. Other collectins, such as surfactant protein A, have strong binding affinities to lipids and  
15 specific cell receptors. Although removal of the CRD abrogates much of this binding, it may be partially mediated by the neck region sequence, which the fusion proteins retain. Accordingly, it would be expected that collectins other than SPD might confer different cell-binding and pharmacokinetic behaviors upon a fusion protein. For example, macrophages are known to take up and degrade whole SPD  
20 [Dong, 1998]. If a fusion protein other than SPD were used, the disposition of the fusion protein *in vivo* might be altered. Additionally, metalloproteinases are known to degrade the collectin, C1q, so that a fusion with C1q may alter the degradation of the fusion protein. For example, because CD40L activates macrophages and other cells to produce metalloproteinases, which could potentially degrade the collagenous  
25 portion of SPD and other collectins. Cleavage of the collagenous stalk would then be expected to release single-trimers of CD40L, which could diffuse away from the

original parent molecule, much like a slow-release formulation of a drug. Also, the membrane-proximal portion of CD40L has been retained in CD40L-SPD. This sequence also contains protease-susceptible amino acid sequences, which can be eliminated by mutagenesis to retard the cleavage of CD40L from the fusion protein.

- 5 Mutations in such proteinase cleavage site(s) would delay such cleavage and favor the local persistence of the CD40L stimulus.

- CD40L-SPD is a large macromolecule ( $> 1,000$  kDa), and the other TNFSF-collectin fusion proteins would be expected to be similarly large. For native SPD,
- 10 the aggregates that spontaneously form measure 100 nm in diameter. When injected into tissue, this large a complex would be expected to remain at the injection site for a prolonged period. Localization of the TNFSF-containing protein would also be expected to reduce any systemic toxicity caused by the release of free single-trimers into the circulation. For example, soluble CD40L in blood has been linked to disease
- 15 activity in lupus, and this smaller molecule may even cross the glomerulus to cause damage to renal tubules [Kato and Kipps, J. Clin. Invest. Nov. 1999]. On the other hand, because CD40L induces the production of chemokines which attract immune cells [Kornbluth], T cells, monocytes, and dendritic cells would be expected migrate to the site where CD40L-SPD was injected. This might be advantageous if CD40L-SPD were used as a vaccine adjuvant. In mice, soluble CD40L (sCD40LT)
- 20 stimulates IgG1 production but not cytotoxic T lymphocytes (CTLs) [Wong, 1999]. Interestingly, the same protein that is expressed from an injected plasmid stimulates both a strong antibody and CTL response [Gurunathan, 1998]. In the latter case, the plasmid would be expected to deliver a localized supply of CD40L, whereas the
- 25 sCD40LT protein is free to diffuse away. Support for the localized use of CD40L in an adjuvant formulation is provided by a study using a plasmid expressing full-length

membrane CD40L, which was very effective in stimulating both humoral and CTL immune responses [Mendoza, 1997]. Similarly, injection of adenovirus expressing membrane CD40L has potent antitumor activity in mice [Kikuchi, 1999]. Similar considerations would likely apply to other fusion proteins between the TNFSF and collectins.

Finally, for immunostimulatory proteins, it is particularly important that the protein not be antigenic if repeated injections are needed. For example, vaccination with TNF- $\mu$  modified by the addition of short peptide sequences was able to induce the production of disease-modifying anti-TNF- $\mu$  autoantibodies [Dalum, 1999]. Because CD40L-SPD and other TNFSF-collectin fusion proteins are formed from endogenous protein sequences (with the possible exception of the peptide sequence at the junction), the production of antibodies might not limit the effectiveness of repeated injections.

In conclusion, fusions between TNFSF members and collectins offer a novel means of generating large protein complexes which can provide localized stimulation at an injection site. Because of the multimeric nature of the collectin backbone, such fusion proteins may mimic the multivalent ligand surface presented by the membrane forms of TNFSF members to TNFRSF-bearing responding cells. Moreover, by limiting systemic toxicity while maintaining localized efficacy, such fusion proteins may have a role as vaccine adjuvants against infectious agents and tumors.

Table I

**Ligands of the TNF Superfamily\***

<u>New Ligand Symbol</u>	<u>Other Names</u>	<u>Genbank ID</u>
LTA	Lymphotoxin-, TNF-?, TNFSF1	X01393
TNF	TNF-?, TNFSF2	X02910
LTB	Lymphotoxin-, TNFSF3	L11016
TNFSF4	OX-40L	D90224
TNFSF5	CD40L, CD154, Gp39, T-BAM	X67878
TNFSF6	FasL	U11821
TNFSF7	CD27L, CD70	L08096
TNFSF8	CD30L	L09753
TNFSF9	4-1BBL	U03398
TNFSF10	TRAIL, Apo-2L	U37518
TNFSF11	RANKL, TRANCE, OPGL, ODF	AF013171
TNFSF12	TWEAK, Apo-3L	AF030099
TNFSF13	APRIL	NM_003808
TNFSF13B	BAFF, THANK, BLYS	AF136293
TNFSF14	LIGHT, HVEM-L	AF036581
TNFSF15	VEGI	AF039390
TNFSF16	unidentified	
TNFSF17	unidentified	
TNFSF18	AITRL, GITRL	AF125303

\*(as of Nov. 1, 1999)

Known members of ligands in the TNF superfamily, taken from the Human Gene

Nomenclature Committee at <http://www.gene.ucl.ac.uk/users/hester/tnftop.htm>

---

Table II

**The Collectin Superfamily**

C1q	Pulmonary surfactant
Mannose-binding protein,	protein D
MBL1	conglutinin
Mannose-binding protein,	collectin-43
MBL2	CL-L1
Pulmonary surfactant	ACRP30
protein A	Hib27

All collectins are formed as multimers of trimeric subunits, each containing a collagenous domain. The C-terminus of each collectin contains a CRD which binds carbohydrates and other ligands. Because of the tight similarities between the known  
5 CRD structures and the extracellular domains of TNFSF members, it is likely that the CRD of any collectin could be replaced with the extracellular domain of any TNFSF member in a structurally compatible manner.

While the present invention has now been described in terms of certain  
10 preferred embodiments, and exemplified with respect thereto, one skilled in the art will readily appreciate that various modifications, changes, omissions and substitutions may be made without departing from the spirit thereof. It is intended, therefore, that the present invention be limited solely by the scope of the following claims.



## CLAIMS

What is claimed is:

- 5           1. A hybrid nucleotide sequence of no more than 1528 base pairs including a sequence defining a structural gene expressing a conjoined single strand of a multimeric TNFSF-SPD fusion protein, said structural gene having a nucleotide base sequence selected from members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5.
- 10           2. The DNA segment according to claim 1, wherein the structural gene comprises:  
a segment expressing a single hybrid amino acid chain of TNFSF-SPD, said segment having  
a first SPD nucleotide base sequence of SEQ ID NO 1, from base 32 to base 799, and  
15           a second sequence, expressing a portion of TNFSF stalk, selected from members of the group consisting of SEQ ID NO 1, from base 800 to base 1444, SEQ ID NO 3, from base 800 to base 1528, and SEQ ID NO 5, from base 800 to base 1441.
- 20           3. A recombinant DNA molecule comprising a vector operatively linked to an exogenous DNA segment defining a structural gene expressing a single amino acid chain of TNFSF-SPD, said structural gene having  
a nucleotide base sequence selected from members of the group consisting of SEQ ID NO 1, SEQ ID NO 3 and SEQ ID NO 5, any functional equivalents and modifications  
25           thereof, and

an appropriate promoter for driving the expression of said structural gene in a compatible host organism.

4. The recombinant DNA molecule as described in claim 3 wherein said host organism  
5 is E. coli.

5. The recombinant DNA molecule as described in claim 3, wherein said host organism is a yeast.

10 6. The recombinant DNA molecule as described in claim 3, wherein said host organism is a higher plant or animal.

7. A multimeric TNFSF-SPD fusion protein comprising:  
a plurality of polypeptide trimers,  
15 i) a first trimer consisting of peptide strands of members of the  
TNF superfamily (TNFSF) of ligands, and  
ii) a second trimer strand from a collectin molecule  
each first trimer conjoined to a second polypeptide trimer strand from  
a collectin molecule, wherein said ligand strand is substituted for native  
20 carbohydrate recognition domains (CRD) of the collectin molecules,  
said conjoined collectin strands covalently bound in parallel to each  
other, therein forming a multimeric fusion protein comprising a plurality of  
trimeric hybrid polypeptide strands radiating from a covalently bound center  
hub of the molecule, the free end of each trimeric radiating strand having a  
25 TNFSF moiety attached.

8. The multimeric fusion protein according to claim 6, wherein the TNFSF moiety is one selected from the group consisting of ligands LTA, TNF, LTB, and TNFSF4 to TNFSF 18 as in Table II, their functional equivalents, and modifications thereof.

5 9. A method for preparing a CD40-SPD multimeric fusion polypeptide, comprising the steps of:

initiating a culture, in a nutrient medium, of procaryotic or eucaryotic host cells transformed with a recombinant DNA molecule including an expression vector, appropriate for said cells, operatively linked to an exogenous DNA segment defining a structural gene  
10 for CD40-SPD ligand, said structural gene having a nucleotide base sequence of SEQ ID NO 1 from about base 32 to about base 1444; and

maintaining said culture for a time period sufficient for said cells to express said multimeric molecule.

15 10. A method of producing a secreted, large, biologically active, multimeric tumor necrosis factor superfamily ligand fusion protein chimera that is highly immunogenic and not readily diffusable, comprising:

introducing into a host cell a first chimeric DNA construct including

a transcriptional promoter operatively linked to a first secretory signal  
20 sequence, followed downstream by, and in proper reading frame with

a first DNA sequence encoding a polypeptide chain of a first TNFSF ligand requiring multimerization for biological activity, joined to

a second DNA sequence encoding a collectin polypeptide at  
25 the site where the collectin's CRD was purposefully removed,

introducing into said host cell a second DNA construct including

a transcriptional promoter operably linked to a second secretory signal sequence followed downstream by, and in proper reading frame with,

a third DNA sequence encoding a second polypeptide chain of a second TNFSF ligand , joined to

a fourth DNA sequence encoding a collectin polypeptide , wherein the collectin's CRD was purposefully removed;

growing said host cell in an appropriate growth medium under physiological conditions to allow the secretion of a large multimerized polypeptide fusion protein, wherein

said first polypeptide chain of a TNFSF-SPD protein is bound by parallel bonding of the respective collectin domain trimer to

said second polypeptide chain of a different TNFSF-SPD polypeptide trimer, and wherein said multimerized polypeptide fusion protein exhibits biological activity characteristic of both membrane-attached TNFSFs; and

isolating said biologically active, multimerized TNFSF-SPD polypeptide fusion from said host cell.

11. The method according to claim 10, wherein the chimeric reactant compounds are humanized to guard against destruction by a potential human recipient's immune system.

12. A method of preparing a multimeric TNFSF-SPD ligand fusion protein, comprising:

preparing a first DNA segment coding for a strand of an exposed extracellular portion of TNFSF;

preparing a second DNA segment coding for a collectin polypeptide strand, wherein said collectin's CRD domain of the strand has been removed;

conjoining said first and second DNAs in proper reading frame, therein creating

a TNFSF-collectin DNA construct;  
inserting said construct into an expression vector system;  
introducing said vector system into an appropriate cell in culture under suitable  
conditions;  
5 harvesting and purifying spent medium from said culture; and  
assaying for presence of multimeric TNFSF-collectin fusion protein.

13. A method for stimulating the immune response in potentially immunocompetent  
cells using multimeric TNFSF fusion proteins, comprising:

10 contacting said cells with said multimeric TNFSF fusion proteins, wherein said cells  
are induced to proliferate.

14. The method according to claim 15, wherein the cells are resting B cells.

15 15. A method for increasing antigenicity of cells, comprising:  
contacting said cells with said multimeric TNFSF fusion proteins, wherein said cells are  
tumor cells or HIV positive cells.

## ABSTRACT

A method for constructing stable bioactive fusion proteins of the difficult to express  
5 tumor necrosis factor superfamily (TNFSF), and particularly members CD40L (CD154) and  
RANKL/TRANCE, with collectins, particularly pulmonary surfactant protein D (SPD) is  
described. Single trimers of these proteins lack the full stimulatory efficacy of the natural  
membrane forms of these proteins in many cases. The multimeric nature of these soluble  
fusion proteins enables them to engage multiple receptors on the responding cells, thereby,  
10 mimicking the effects of the membrane forms of these ligands. For CD40L-SPD, the  
resulting protein stimulates B cells, macrophages, and dendritic cells, indicating its potential  
usefulness as a vaccine adjuvant. The large size of these fusion proteins makes them less  
likely to diffuse into the circulation, thereby limiting their potential systemic toxicity. This  
property may be especially useful when these proteins are injected locally as a vaccine  
15 adjuvant or tumor immunotherapy agent to prevent them from diffusing away. In addition,  
these and other TNFSF-collectin fusion proteins present new possibilities for the expression  
of highly active, multimeric, soluble TNFSF members.

Nhe I

C15 C20

Collagen-like Domain

Extracellular CD40L/IT147NCD40L

Kpn I




Fig. 1

Purification of murine  
CD40L-SPD by cationic  
exchange chromatography




Fig 2.



## Ultrafiltration sizing of CD40L-SPD




Fig. 3





Fig. 4

## Stimulation of Resting Murine B Cells




Fig. 5




Fig. 6

# RANKL/TRANSE ELISA




Fig. 7.

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
**PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY**  
(Page 1 of 2)

EACH OF THE APPLICANTS SIGNING BELOW HEREBY DECLARES THAT:

My residence, post office address, and citizenship are as stated next to my name in PART A on page 2 hereof.

I believe that I am an original, first, and joint inventor of the subject matter which is claimed and for which a patent is sought on the invention entitled **MULTIMERIC FORMS OF TNF SUPERFAMILY LIGANDS**, the specification of which is attached hereto. Priority of provisional application No. 60/111,471 Filing Date: 12/09/98 is hereby claimed.

I hereby state that I have reviewed and understood the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby declare that all statements made herein of my knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent(s) issued thereon.

I hereby appoint as my attorney with full power of substitution to prosecute this application and transact all business in the United States Patent and Trademark Office connected therewith:

William C. Fuess      Registration Number 30,054

whose mailing address for this application is:

William C. Fuess  
Attorney at Law  
11080 Roselle Street, Suite E1  
San Diego, California 92121  
Attention: William C. Fuess

and whose telecommunications numbers are:

Telephone: (619) 452-8293  
Facsimile: (619) 452-8293

All correspondence and telephone calls should be directed to William C. Fuess at the address and telephone number referenced above.

See next page 2 attached, signed, and made a part hereof.

PATENT APPLICATION DECLARATION AND POWER OF ATTORNEY  
(Page 2 of 2)

PART A: Inventors' Information and Signatures

Full Name of First Inventor: Richard S. Kornbluth  
Citizenship: United States  
Post Office Address: 5415 Taft Ave, La Jolla, CA, 92037-7641  
Residence (if different): \_\_\_\_\_  
Inventor's Signature: Richard S. Kornbluth  
Date: December 9, 1999

Full Name of Second Inventor: \_\_\_\_\_  
Citizenship: \_\_\_\_\_  
Post Office Address: \_\_\_\_\_  
Residence (if different): \_\_\_\_\_  
Inventor's Signature: \_\_\_\_\_  
Date: \_\_\_\_\_

Full Name of Third Inventor: \_\_\_\_\_  
Citizenship: \_\_\_\_\_  
Post Office Address: \_\_\_\_\_  
Residence (if different): \_\_\_\_\_  
Inventor's Signature: \_\_\_\_\_  
Date: \_\_\_\_\_

See page 1 to which this page is attached and of which this page is a part.

# SEQUENCE LISTING

<110> Kornbluth, Richard S

<120> Multimeric forms of CD40L and other TNF family members

<130> TNFSF-collectin fusion proteins

<140> 60/111,471

<141> 1998-12-08

<160> 6

<170> PatentIn Ver. 2.1

<210> 1 .

<211> 1552

<212> DNA

<213> Artificial Sequence

<220>

<221> 5'UTR

<222> (7)..(31)

<220>

<221> misc\_feature

<222> (88)..(799)

<223> Mature murine surfactant protein D including hub region, collagenous portion, and neck, but excluding carbohydrate recognition domain (CRD)

<220>

<221> misc\_feature

<222> (801)..(1546)

<223> Human CD40 ligand extracellular region, including stalk.

<220>

<221> sig\_peptide

<222> (32)..(88)

<223> Signal peptide from murine surfactant protein D

<220>

<221> CDS

<222> (32)..(1444)

<220>

<223> Description of Artificial Sequence: Murine



surfactant protein D (without the CRD) fused to  
the extracellular portion of human CD40L

<300>

<301> Spriggs, Melanie K.  
Armitage, Richard J.  
Strockbine, L  
Clifford, K N.  
Macduff, B M.  
Sato, T A.  
Maliszewski, C R.  
Fanslow, William C.

<302> Recombinant human CD40 ligand stimulates B cell  
proliferation and immunoglobulin E secretion.

<303> J. Exp. Med.

<304> 176

<305> 6

<306> 1543-1550

<307> 1992

<313> 801 TO 1600

<300>

<301> Motwani, M  
White, R A.

<302> Mouse surfactant protein-D. cDNA cloning,  
characterization, and gene localization to chromosome  
14.

<303> J. Immunol.

<304> 155

<305> 12

<306> 5671-5677

<307> 1995

<313> 32 TO 800

<400> 1

gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg	52
Met Leu Pro Phe Leu Ser Met	
1 5	

ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag	100
Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys	
10 15 20	

agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt	148
Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys	
25 30 35	

agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga	196
---	-----

Ser	Pro	Thr	Glu	Asn	Gly	Leu	Pro	Gly	Arg	Asp	Gly	Arg	Asp	Gly	Arg	
40					45				50					55		
gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg																244
Glu	Gly	Pro	Arg	Gly	Glu	Lys	Gly	Asp	Pro	Gly	Leu	Pro	Gly	Pro	Met	
				60				65						70		
ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga																292
Gly	Leu	Ser	Gly	Leu	Gln	Gly	Pro	Thr	Gly	Pro	Val	Gly	Pro	Lys	Gly	
			75				80					85				
gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta																340
Glu	Asn	Gly	Ser	Ala	Gly	Glu	Pro	Gly	Pro	Lys	Gly	Glu	Arg	Gly	Leu	
		90					95					100				
agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa																388
Ser	Gly	Pro	Pro	Gly	Leu	Pro	Gly	Ile	Pro	Gly	Pro	Ala	Gly	Lys	Glu	
	105					110				115						
ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt																436
Gly	Pro	Ser	Gly	Lys	Gln	Gly	Asn	Ile	Gly	Pro	Gln	Gly	Lys	Pro	Gly	
120					125					130				135		
cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg																484
Pro	Lys	Gly	Glu	Ala	Gly	Pro	Lys	Gly	Glu	Val	Gly	Ala	Pro	Gly	Met	
				140					145					150		
caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga																532
Gln	Gly	Ser	Thr	Gly	Ala	Lys	Gly	Ser	Thr	Gly	Pro	Lys	Gly	Glu	Arg	
			155				160						165			
ggt gcc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga																580
Gly	Ala	Pro	Gly	Val	Gln	Gly	Ala	Pro	Gly	Asn	Ala	Gly	Ala	Ala	Gly	
		170				175					180					
cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc																628
Pro	Ala	Gly	Pro	Ala	Gly	Pro	Gln	Gly	Ala	Pro	Gly	Ser	Arg	Gly	Pro	
		185				190					195					
cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa																676
Pro	Gly	Leu	Lys	Gly	Asp	Arg	Gly	Val	Pro	Gly	Asp	Arg	Gly	Ile	Lys	
200					205					210				215		
ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag																724
Gly	Glu	Ser	Gly	Leu	Pro	Asp	Ser	Ala	Ala	Leu	Arg	Gln	Gln	Met	Glu	
				220				225						230		
gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat																772

Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr  
 235 240 245

cag aaa gct gca ttg ttc cct gat ggc cat aga agg ttg gac aag ata 820  
 Gln Lys Ala Ala Leu Phe Pro Asp Gly His Arg Arg Leu Asp Lys Ile  
 250 255 260

gaa gat gaa agg aat ctt cat gaa gat ttt gta ttc atg aaa acg ata 868  
 Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met Lys Thr Ile  
 265 270 275

cag aga tgc aac aca gga gaa aga tcc tta tcc tta ctg aac tgt gag 916  
 Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu Asn Cys Glu  
 280 285 290 295

gag att aaa agc cag ttt gaa ggc ttt gtg aag gat ata atg tta aac 964  
 Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile Met Leu Asn  
 300 305 310

aaa gag gag acg aag aaa gaa aac agc ttt gaa atg caa aaa ggt gat 1012  
 Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln Lys Gly Asp  
 315 320 325

cag aat cct caa att gcg gca cat gtc ata agt gag gcc agc agt aaa 1060  
 Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala Ser Ser Lys  
 330 335 340

aca aca tct gtg tta cag tgg gct gaa aaa gga tac tac acc atg agc 1108  
 Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr Thr Met Ser  
 345 350 355

aac aac ttg gta acc ctg gaa aat ggg aaa cag ctg acc gtt aaa aga 1156  
 Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr Val Lys Arg  
 360 365 370 375

caa gga ctc tat tat atc tat gcc caa gtc acc ttc tgt tcc aat cgg 1204  
 Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys Ser Asn Arg  
 380 385 390

gaa gct tcg agt caa gct cca ttt ata gcc agc ctc tgc cta aag tcc 1252  
 Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys Leu Lys Ser  
 395 400 405

ccc ggt aga ttc gag aga atc tta ctc aga gct gca aat acc cac agt 1300  
 Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn Thr His Ser  
 410 415 420

tcc gcc aaa cct tgc ggg caa caa tcc att cac ttg gga gga gta ttt 1348

Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly Gly Val Phe  
 425 430 435

gaa ttg caa cca ggt gct tcg gtg ttt gtc aat gtg act gat cca agc 1396  
 Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr Asp Pro Ser  
 440 445 450 455

caa gtg agc cat ggc act ggc ttc acg tcc ttt ggc tta ctc aaa ctc 1444  
 Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu Leu Lys Leu  
 460 465 470

tgaacagtgt caccttcgag gctgtggtgg agctgacgct gggagtcttc ataatacagc 1504

acaggcttaa gcccaattat acactccaag gcatgtagaa ctggtacc 1552

<210> 2

<211> 471

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Murine  
 surfactant protein D (without the CRD) fused to  
 the extracellular portion of human CD40L

<400> 2

Met Leu Pro Phe Leu Ser Met Leu Val Leu Leu Val Gln Pro Leu Gly  
 1 5 10 15

Asn Leu Gly Ala Glu Met Lys Ser Leu Ser Gln Arg Ser Val Pro Asn  
 20 25 30

Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly  
 35 40 45

Arg Asp Gly Arg Asp Gly Arg Glu Gly Pro Arg Gly Glu Lys Gly Asp  
 50 55 60

Pro Gly Leu Pro Gly Pro Met Gly Leu Ser Gly Leu Gln Gly Pro Thr  
 65 70 75 80

Gly Pro Val Gly Pro Lys Gly Glu Asn Gly Ser Ala Gly Glu Pro Gly  
 85 90 95

Pro Lys Gly Glu Arg Gly Leu Ser Gly Pro Pro Gly Leu Pro Gly Ile  
 100 105 110

Pro Gly Pro Ala Gly Lys Glu Gly Pro Ser Gly Lys Gln Gly Asn Ile  
 115 120 125

Gly Pro Gln Gly Lys Pro Gly Pro Lys Gly Glu Ala Gly Pro Lys Gly  
130 135 140

Glu Val Gly Ala Pro Gly Met Gln Gly Ser Thr Gly Ala Lys Gly Ser  
145 150 155 160

Thr Gly Pro Lys Gly Glu Arg Gly Ala Pro Gly Val Gln Gly Ala Pro  
165 170 175

Gly Asn Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Gln Gly  
180 185 190

Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val  
195 200 205

Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala  
210 215 220

Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu  
225 230 235 240

Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly  
245 250 255

His Arg Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp  
260 265 270

Phe Val Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser  
275 280 285

Leu Ser Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe  
290 295 300

Val Lys Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser  
305 310 315 320

Phe Glu Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val  
325 330 335

Ile Ser Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu  
340 345 350

Lys Gly Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly  
355 360 365

Lys Gln Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln  
370 375 380

Val Thr Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile  
385 390 395 400

Ala Ser Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu  
405 410 415

Arg Ala Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser  
420 425 430

Ile His Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe  
435 440 445

Val Asn Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr  
450 455 460

Ser Phe Gly Leu Leu Lys Leu  
465 470

<210> 3

<211> 1574

<212> DNA

<213> Artificial Sequence

<220>

<221> 5'UTR

<222> (7)..(31)

<223> 5' UTR taken from rat sequence for surfactant  
protein D

<220>

<221> sig\_peptide

<222> (32)..(88)

<223> Signal peptide from murine surfactant protein D

<220>

<221> CDS

<222> (32)..(1534)

<220>

<221> misc\_feature

<222> (32)..(800)

<223> Murine surfactant protein D including hub region,  
collagenous portion, and neck, but excluding  
carbohydrate recognition domain (CRD)

<220>  
 <221> misc\_feature  
 <222> (801)..(1534)  
 <223> Murine RANKL/TRANCE extracellular region,  
 including stalk  
  
 <300>  
 <301> Motwani, M  
 White, R A.  
 Guo, N  
 Dowler, L L.  
 Tauber, A I.  
 Motwani, M  
 <302> Mouse surfactant protein-D. cDNA cloning,  
 characterization, and gene localization to chromosome  
 14.  
 <303> J. Immunol.  
 <304> 155  
 <305> 12  
 <306> 5671-5677  
 <307> 1995  
 <313> 32 TO 800

<300>  
 <301> Anderson, D M.  
 Maraskovsky, E  
 Billingsley, W L.  
 Dougall, W C.  
 <302> A homologue of the TNF receptor and its ligand enhance  
 T-cell growth and dendritic-cell function.  
 <303> Nature  
 <304> 390  
 <305> 6656  
 <306> 175-179  
 <307> 1997  
 <313> 801 TO 1534

<400> 3  
 gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg 52  
 Met Leu Pro Phe Leu Ser Met  
 1 5  
  
 ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag 100  
 Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys  
 10 15 20  
  
 agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt 148  
 Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys

25

30

35

agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga 196  
 Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg  
 40 45 50 55

gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg 244  
 Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met  
 60 65 70

ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga 292  
 Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly  
 75 80 85

gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta 340  
 Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu  
 90 95 100

agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa 388  
 Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu  
 105 110 115

ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt 436  
 Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly  
 120 125 130 135

cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg 484  
 Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met  
 140 145 150

caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga 532  
 Gln Gly Ser Thr Gly Ala Lys Gly Ser Thr Gly Pro Lys Gly Glu Arg  
 155 160 165

ggt gcc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga 580  
 Gly Ala Pro Gly Val Gln Gly Ala Pro Gly Asn Ala Gly Ala Ala Gly  
 170 175 180

cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc 628  
 Pro Ala Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Ser Arg Gly Pro  
 185 190 195

cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa 676  
 Pro Gly Leu Lys Gly Asp Arg Gly Val Pro Gly Asp Arg Gly Ile Lys  
 200 205 210 215

ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag 724  
 Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu



220	225	230	
gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat			772
Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr			
235	240	245	
cag aaa gct gca ttg ttc cct gat ggt cga gcg cag atg gat cct aac			820
Gln Lys Ala Ala Leu Phe Pro Asp Gly Arg Ala Gln Met Asp Pro Asn			
250	255	260	
aga ata tca gaa gac agc act cac tgc ttt tat aga atc ctg aga ctc			868
Arg Ile Ser Glu Asp Ser Thr His Cys Phe Tyr Arg Ile Leu Arg Leu			
265	270	275	
cat gaa aac gca ggt ttg cag gac tcg act ctg gag agt gaa gac aca			916
His Glu Asn Ala Gly Leu Gln Asp Ser Thr Leu Glu Ser Glu Asp Thr			
280	285	290	295
cta cct gac tcc tgc agg agg atg aaa caa gcc ttt cag ggg gcc gtg			964
Leu Pro Asp Ser Cys Arg Arg Met Lys Gln Ala Phe Gln Gly Ala Val			
300	305	310	
cag aag gaa ctg caa cac att gtg ggg cca cag cgc ttc tca gga gct			1012
Gln Lys Glu Leu Gln His Ile Val Gly Pro Gln Arg Phe Ser Gly Ala			
315	320	325	
cca gct atg atg gaa ggc tca tgg ttg gat gtg gcc cag cga ggc aag			1060
Pro Ala Met Met Glu Gly Ser Trp Leu Asp Val Ala Gln Arg Gly Lys			
330	335	340	
cct gag gcc cag cca ttt gca cac ctc acc atc aat gct gcc agc atc			1108
Pro Glu Ala Gln Pro Phe Ala His Leu Thr Ile Asn Ala Ala Ser Ile			
345	350	355	
cca tcg ggt tcc cat aaa gtc act ctg tcc tct tgg tac cac gat cga			1156
Pro Ser Gly Ser His Lys Val Thr Leu Ser Ser Trp Tyr His Asp Arg			
360	365	370	375
ggc tgg gcc aag atc tct aac atg acg tta agc aac gga aaa cta agg			1204
Gly Trp Ala Lys Ile Ser Asn Met Thr Leu Ser Asn Gly Lys Leu Arg			
380	385	390	
gtt aac caa gat ggc ttc tat tac ctg tac gcc aac att tgc ttt cgg			1252
Val Asn Gln Asp Gly Phe Tyr Tyr Leu Tyr Ala Asn Ile Cys Phe Arg			
395	400	405	
cat cat gaa aca tcg gga agc gta cct aca gac tat ctt cag ctg atg			1300
His His Glu Thr Ser Gly Ser Val Pro Thr Asp Tyr Leu Gln Leu Met			

410 415 420

gtg tat gtc gtt aaa acc agc atc aaa atc cca agt tct cat aac ctg 1348  
Val Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu  
425 430 435

atg aaa gga ggg agc acg aaa aac tgg tgc ggc aat tct gaa ttc cac 1396  
Met Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His  
440 445 450 455

ttt tat tcc ata aat gtt ggg gga ttt ttc aag ctc cga gct ggt gaa 1444  
Phe Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu  
460 465 470

gaa att agc att cag gtg tcc aac cct tcc ctg ctg gat ccg gat caa 1492  
Glu Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln  
475 480 485

gat gcg acg tac ttt ggg gct ttc aaa gtt cag gac ata gac 1534  
Asp Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
490 495 500

tgagactcat ttcgtggaac attagcggcc gctaaactat 1574

<210> 4  
<211> 501  
<212> PRT  
<213> Artificial Sequence

<400> 4  
Met Leu Pro Phe Leu Ser Met Leu Val Leu Leu Val Gln Pro Leu Gly  
1 5 10 15  
Asn Leu Gly Ala Glu Met Lys Ser Leu Ser Gln Arg Ser Val Pro Asn  
20 25 30  
Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly  
35 40 45  
Arg Asp Gly Arg Asp Gly Arg Glu Gly Pro Arg Gly Glu Lys Gly Asp  
50 55 60  
Pro Gly Leu Pro Gly Pro Met Gly Leu Ser Gly Leu Gln Gly Pro Thr  
65 70 75 80  
Gly Pro Val Gly Pro Lys Gly Glu Asn Gly Ser Ala Gly Glu Pro Gly  
85 90 95

Pro Lys Gly Glu Arg Gly Leu Ser Gly Pro Pro Gly Leu Pro Gly Ile  
 100 105 110

Pro Gly Pro Ala Gly Lys Glu Gly Pro Ser Gly Lys Gln Gly Asn Ile  
 115 120 125

Gly Pro Gln Gly Lys Pro Gly Pro Lys Gly Glu Ala Gly Pro Lys Gly  
 130 135 140

Glu Val Gly Ala Pro Gly Met Gln Gly Ser Thr Gly Ala Lys Gly Ser  
 145 150 155 160

Thr Gly Pro Lys Gly Glu Arg Gly Ala Pro Gly Val Gln Gly Ala Pro  
 165 170 175

Gly Asn Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Gln Gly  
 180 185 190

Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val  
 195 200 205

Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala  
 210 215 220

Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu  
 225 230 235 240

Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly  
 245 250 255

Arg Ala Gln Met Asp Pro Asn Arg Ile Ser Glu Asp Ser Thr His Cys  
 260 265 270

Phe Tyr Arg Ile Leu Arg Leu His Glu Asn Ala Gly Leu Gln Asp Ser  
 275 280 285

Thr Leu Glu Ser Glu Asp Thr Leu Pro Asp Ser Cys Arg Arg Met Lys  
 290 295 300

Gln Ala Phe Gln Gly Ala Val Gln Lys Glu Leu Gln His Ile Val Gly  
 305 310 315 320

Pro Gln Arg Phe Ser Gly Ala Pro Ala Met Met Glu Gly Ser Trp Leu  
 325 330 335

Asp Val Ala Gln Arg Gly Lys Pro Glu Ala Gln Pro Phe Ala His Leu  
 340 345 350

Thr Ile Asn Ala Ala Ser Ile Pro Ser Gly Ser His Lys Val Thr Leu  
 355 360 365  
 Ser Ser Trp Tyr His Asp Arg Gly Trp Ala Lys Ile Ser Asn Met Thr  
 370 375 380  
 Leu Ser Asn Gly Lys Leu Arg Val Asn Gln Asp Gly Phe Tyr Tyr Leu  
 385 390 395 400  
 Tyr Ala Asn Ile Cys Phe Arg His His Glu Thr Ser Gly Ser Val Pro  
 405 410 415  
 Thr Asp Tyr Leu Gln Leu Met Val Tyr Val Val Lys Thr Ser Ile Lys  
 420 425 430  
 Ile Pro Ser Ser His Asn Leu Met Lys Gly Gly Ser Thr Lys Asn Trp  
 435 440 445  
 Ser Gly Asn Ser Glu Phe His Phe Tyr Ser Ile Asn Val Gly Gly Phe  
 450 455 460  
 Phe Lys Leu Arg Ala Gly Glu Glu Ile Ser Ile Gln Val Ser Asn Pro  
 465 470 475 480  
 Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr Tyr Phe Gly Ala Phe Lys  
 485 490 495  
 Val Gln Asp Ile Asp  
 500

<210> 5

<211> 1477

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Murine  
 surfactant protein D (except CRD) fused to the  
 extracellular domain of murine CD40 ligand

<220>

<221> 5'UTR

<222> (7)..(31)

<223> 5' UTR from rat surfactant protein D

<220>  
 <221> sig\_peptide  
 <222> (32)..(88)  
 <223> Signal peptide from murine surfactant protein D

<220>  
 <221> CDS  
 <222> (32)..(1441)

<220>  
 <221> misc\_recomb  
 <222> (88)..(799)  
 <223> Mature murine surfactant protein D including hub  
 region, collagenous portion, and neck, but  
 excluding carbohydrate recognition domain (CRD)

<220>  
 <221> misc\_feature  
 <222> (800)..(1441)  
 <223> Murine CD40 ligand extracellular region, including  
 stalk

<300>  
 <301> Motwani, M  
 White, R A.  
 Guo, N  
 Dowler, L L.  
 Tauber, A I.  
 Motwani, M  
 <302> Mouse surfactant protein-D. cDNA cloning,  
 characterization, and gene localization to chromosome  
 14.  
 <303> J. Immunol.  
 <304> 155  
 <305> 12  
 <306> 5671-5677  
 <307> 1995  
 <313> 32 TO 800

<300>  
 <301> Armitage, R  
 Fanslow, W  
 Sato, T A.  
 Clifford, K N.  
 <302> Molecular and biological characterization of a murine  
 ligand for CD40  
 <303> Nature  
 <304> 357

<305> 6373  
 <306> 80-82  
 <307> 1992  
 <313> 801 TO 1441

<400> 5

gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg	52
Met Leu Pro Phe Leu Ser Met	
1 5	
ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag	100
Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys	
10 15 20	
agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt	148
Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys	
25 30 35	
agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga	196
Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg	
40 45 50 55	
gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg	244
Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met	
60 65 70	
ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga	292
Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly	
75 80 85	
gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta	340
Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu	
90 95 100	
agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa	388
Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu	
105 110 115	
ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt	436
Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly	
120 125 130 135	
cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg	484
Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met	
140 145 150	
caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga	532
Gln Gly Ser Thr Gly Ala Lys Gly Ser Thr Gly Pro Lys Gly Glu Arg	

155	160	165	
ggt gcc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga			580
Gly Ala Pro Gly Val Gln Gly Ala Pro Gly Asn Ala Gly Ala Ala Gly			
170	175	180	
cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc			628
Pro Ala Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Ser Arg Gly Pro			
185	190	195	
cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa			676
Pro Gly Leu Lys Gly Asp Arg Gly Val Pro Gly Asp Arg Gly Ile Lys			
200	205	210	215
ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag			724
Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu			
220	225	230	
gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat			772
Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr			
235	240	245	
cag aaa gct gca ttg ttc cct gat ggc cat aga aga ttg gat aag gtc			820
Gln Lys Ala Ala Leu Phe Pro Asp Gly His Arg Arg Leu Asp Lys Val			
250	255	260	
gaa gag gaa gta aac ctt cat gaa gat ttt gta ttc ata aaa aag cta			868
Glu Glu Glu Val Asn Leu His Glu Asp Phe Val Phe Ile Lys Lys Leu			
265	270	275	
aag aga tgc aac aaa gga gaa gga tct tta tcc ttg ctg aac tgt gag			916
Lys Arg Cys Asn Lys Gly Glu Gly Ser Leu Ser Leu Leu Asn Cys Glu			
280	285	290	295
gag atg aga agg caa ttt gaa gac ctt gtc aag gat ata acg tta aac			964
Glu Met Arg Arg Gln Phe Glu Asp Leu Val Lys Asp Ile Thr Leu Asn			
300	305	310	
aaa gaa gag aaa aaa gaa aac agc ttt gaa atg caa aga ggt gat gag			1012
Lys Glu Glu Lys Lys Glu Asn Ser Phe Glu Met Gln Arg Gly Asp Glu			
315	320	325	
gat cct caa att gca gca cac gtt gta agc gaa gcc aac agt aat gca			1060
Asp Pro Gln Ile Ala Ala His Val Val Ser Glu Ala Asn Ser Asn Ala			
330	335	340	
gca tcc gtt cta cag tgg gcc aag aaa gga tat tat acc atg aaa agc			1108
Ala Ser Val Leu Gln Trp Ala Lys Lys Gly Tyr Tyr Thr Met Lys Ser			

345	350	355	
aac ttg gta atg ctt gaa aat ggg aaa cag ctg acg gtt aaa aga gaa			1156
Asn Leu Val Met Leu Glu Asn Gly Lys Gln Leu Thr Val Lys Arg Glu			
360	365	370	375
gga ctc tat tat gtc tac act caa gtc acc ttc tgc tct aat cgg gag			1204
Gly Leu Tyr Tyr Val Tyr Thr Gln Val Thr Phe Cys Ser Asn Arg Glu			
	380	385	390
cct tcg agt caa cgc cca ttc atc gtc ggc ctc tgg ctg aag ccc agc			1252
Pro Ser Ser Gln Arg Pro Phe Ile Val Gly Leu Trp Leu Lys Pro Ser			
	395	400	405
att gga tct gag aga atc tta ctc aag gcg gca aat acc cac agt tcc			1300
Ile Gly Ser Glu Arg Ile Leu Leu Lys Ala Ala Asn Thr His Ser Ser			
	410	415	420
tcc cag ctt tgc gag cag cag tct gtt cac ttg ggc gga gtg ttt gaa			1348
Ser Gln Leu Cys Glu Gln Gln Ser Val His Leu Gly Gly Val Phe Glu			
	425	430	435
tta caa gct ggt gct tct gtg ttt gtc aac gtg act gaa gca agc caa			1396
Leu Gln Ala Gly Ala Ser Val Phe Val Asn Val Thr Glu Ala Ser Gln			
	440	445	450
gtg atc cac aga gtt ggc ttc tca tct ttt ggc tta ctc aaa ctc			1441
Val Ile His Arg Val Gly Phe Ser Ser Phe Gly Leu Leu Lys Leu			
	460	465	470
tgaacagtgc gctgtcctag gctgcagcag ggtacc			1477

<210> 6

<211> 470

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Murine  
surfactant protein D (except CRD) fused to the  
extracellular domain of murine CD40 ligand

<400> 6

Met	Leu	Pro	Phe	Leu	Ser	Met	Leu	Val	Leu	Leu	Val	Gln	Pro	Leu	Gly
1				5					10					15	

Asn	Leu	Gly	Ala	Glu	Met	Lys	Ser	Leu	Ser	Gln	Arg	Ser	Val	Pro	Asn
		20						25					30		



Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly  
 35 40 45

Arg Asp Gly Arg Asp Gly Arg Glu Gly Pro Arg Gly Glu Lys Gly Asp  
 50 55 60

Pro Gly Leu Pro Gly Pro Met Gly Leu Ser Gly Leu Gln Gly Pro Thr  
 65 70 75 80

Gly Pro Val Gly Pro Lys Gly Glu Asn Gly Ser Ala Gly Glu Pro Gly  
 85 90 95

Pro Lys Gly Glu Arg Gly Leu Ser Gly Pro Pro Gly Leu Pro Gly Ile  
 100 105 110

Pro Gly Pro Ala Gly Lys Glu Gly Pro Ser Gly Lys Gln Gly Asn Ile  
 115 120 125

Gly Pro Gln Gly Lys Pro Gly Pro Lys Gly Glu Ala Gly Pro Lys Gly  
 130 135 140

Glu Val Gly Ala Pro Gly Met Gln Gly Ser Thr Gly Ala Lys Gly Ser  
 145 150 155 160

Thr Gly Pro Lys Gly Glu Arg Gly Ala Pro Gly Val Gln Gly Ala Pro  
 165 170 175

Gly Asn Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Gln Gly  
 180 185 190

Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val  
 195 200 205

Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala  
 210 215 220

Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu  
 225 230 235 240

Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly  
 245 250 255

His Arg Arg Leu Asp Lys Val Glu Glu Glu Val Asn Leu His Glu Asp  
 260 265 270

Phe Val Phe Ile Lys Lys Leu Lys Arg Cys Asn Lys Gly Glu Gly Ser  
 275 280 285

Leu Ser Leu Leu Asn Cys Glu Glu Met Arg Arg Gln Phe Glu Asp Leu  
 290 295 300

Val Lys Asp Ile Thr Leu Asn Lys Glu Glu Lys Lys Glu Asn Ser Phe  
 305 310 315 320

Glu Met Gln Arg Gly Asp Glu Asp Pro Gln Ile Ala Ala His Val Val  
 325 330 335

Ser Glu Ala Asn Ser Asn Ala Ala Ser Val Leu Gln Trp Ala Lys Lys  
 340 345 350

Gly Tyr Tyr Thr Met Lys Ser Asn Leu Val Met Leu Glu Asn Gly Lys  
 355 360 365

Gln Leu Thr Val Lys Arg Glu Gly Leu Tyr Tyr Val Tyr Thr Gln Val  
 370 375 380

Thr Phe Cys Ser Asn Arg Glu Pro Ser Ser Gln Arg Pro Phe Ile Val  
 385 390 395 400

Gly Leu Trp Leu Lys Pro Ser Ile Gly Ser Glu Arg Ile Leu Leu Lys  
 405 410 415


Ala Ala Asn Thr His Ser Ser Ser Gln Leu Cys Glu Gln Gln Ser Val  
 420 425 430

His Leu Gly Gly Val Phe Glu Leu Gln Ala Gly Ala Ser Val Phe Val  
 435 440 445

Asn Val Thr Glu Ala Ser Gln Val Ile His Arg Val Gly Phe Ser Ser  
 450 455 460

Phe Gly Leu Leu Lys Leu  
 465 470

12.13.99



SEQUENCE LISTING

<110> Kornbluth, Richard S

<120> Multimeric forms of CD40L and other TNF family members

<130> TNFSF-collectin fusion proteins

<140> 60/111,471

<141> 1998-12-08

<160> 6

<170> PatentIn Ver. 2.1

<210> 1

<211> 1552

<212> DNA

<213> Artificial Sequence

<220>

<221> 5'UTR

<222> (7)..(31)

<220>

<221> misc\_feature

<222> (88)..(799)

<223> Mature murine surfactant protein D including hub region, collagenous portion, and neck, but excluding carbohydrate recognition domain (CRD)

<220>

<221> misc\_feature

<222> (801)..(1546)

<223> Human CD40 ligand extracellular region, including stalk.

<220>

<221> sig\_peptide

<222> (32)..(88)

<223> Signal peptide from murine surfactant protein D

<220>

<221> CDS

<222> (32)..(1444)

<220>

<223> Description of Artificial Sequence: Murine surfactant protein D (without the CRD) fused to the extracellular portion of human CD40L

<300>

<301> Spriggs, Melanie K.

Armitage, Richard J.

Strockbine, L  
 Clifford, K N.  
 Macduff, B M.  
 Sato, T A.  
 Maliszewski, C R.  
 Fanslow, William C.

<302> Recombinant human CD40 ligand stimulates B cell  
 proliferation and immunoglobulin E secretion.

<303> J. Exp. Med.

<304> 176

<305> 6

<306> 1543-1550

<307> 1992

<313> 801 TO 1600

<300>

<301> Motwani, M

White, R A.

<302> Mouse surfactant protein-D. cDNA cloning,  
 characterization, and gene localization to chromosome  
 14.

<303> J. Immunol.

<304> 155

<305> 12

<306> 5671-5677

<307> 1995

<313> 32 TO 800

<400> 1

gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg 52

Met Leu Pro Phe Leu Ser Met

1 5

ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag 100

Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys

10 15 20

agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt 148

Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys

25 30 35

agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga 196

Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg

40 45 50 55

gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg 244

Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met

60 65 70

ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga 292

Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly

75 80 85

gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta 340

Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu  
90 95 100

agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa 388  
Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu  
105 110 115

ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt 436  
Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly  
120 125 130 135

cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg 484  
Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met  
140 145 150

caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga 532  
Gln Gly Ser Thr Gly Ala Lys Gly Ser Thr Gly Pro Lys Gly Glu Arg  
155 160 165

ggt gcc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga 580  
Gly Ala Pro Gly Val Gln Gly Ala Pro Gly Asn Ala Gly Ala Ala Gly  
170 175 180

cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc 628  
Pro Ala Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Ser Arg Gly Pro  
185 190 195

cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa 676  
Pro Gly Leu Lys Gly Asp Arg Gly Val Pro Gly Asp Arg Gly Ile Lys  
200 205 210 215

ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag 724  
Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu  
220 225 230

gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat 772  
Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr  
235 240 245

cag aaa gct gca ttg ttc cct gat ggc cat aga agg ttg gac aag ata 820  
Gln Lys Ala Ala Leu Phe Pro Asp Gly His Arg Arg Leu Asp Lys Ile  
250 255 260

gaa gat gaa agg aat ctt cat gaa gat ttt gta ttc atg aaa acg ata 868  
Glu Asp Glu Arg Asn Leu His Glu Asp Phe Val Phe Met Lys Thr Ile  
265 270 275

cag aga tgc aac aca gga gaa aga tcc tta tcc tta ctg aac tgt gag 916  
Gln Arg Cys Asn Thr Gly Glu Arg Ser Leu Ser Leu Leu Asn Cys Glu  
280 285 290 295

gag att aaa agc cag ttt gaa ggc ttt gtg aag gat ata atg tta aac 964  
Glu Ile Lys Ser Gln Phe Glu Gly Phe Val Lys Asp Ile Met Leu Asn  
300 305 310

aaa gag gag acg aag aaa gaa aac agc ttt gaa atg caa aaa ggt gat 1012  
 Lys Glu Glu Thr Lys Lys Glu Asn Ser Phe Glu Met Gln Lys Gly Asp  
 315 320 325

cag aat cct caa att gcg gca cat gtc ata agt gag gcc agc agt aaa 1060  
 Gln Asn Pro Gln Ile Ala Ala His Val Ile Ser Glu Ala Ser Ser Lys  
 330 335 340

aca aca tct gtg tta cag tgg gct gaa aaa gga tac tac acc atg agc 1108  
 Thr Thr Ser Val Leu Gln Trp Ala Glu Lys Gly Tyr Tyr Thr Met Ser  
 345 350 355

aac aac ttg gta acc ctg gaa aat ggg aaa cag ctg acc gtt aaa aga 1156  
 Asn Asn Leu Val Thr Leu Glu Asn Gly Lys Gln Leu Thr Val Lys Arg  
 360 365 370 375

caa gga ctc tat tat atc tat gcc caa gtc acc ttc tgt tcc aat cgg 1204  
 Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln Val Thr Phe Cys Ser Asn Arg  
 380 385 390

gaa gct tcg agt caa gct cca ttt ata gcc agc ctc tgc cta aag tcc 1252  
 Glu Ala Ser Ser Gln Ala Pro Phe Ile Ala Ser Leu Cys Leu Lys Ser  
 395 400 405

ccc ggt aga ttc gag aga atc tta ctc aga gct gca aat acc cac agt 1300  
 Pro Gly Arg Phe Glu Arg Ile Leu Leu Arg Ala Ala Asn Thr His Ser  
 410 415 420

tcc gcc aaa cct tgc ggg caa caa tcc att cac ttg gga gga gta ttt 1348  
 Ser Ala Lys Pro Cys Gly Gln Gln Ser Ile His Leu Gly Gly Val Phe  
 425 430 435

gaa ttg caa cca ggt gct tcg gtg ttt gtc aat gtg act gat cca agc 1396  
 Glu Leu Gln Pro Gly Ala Ser Val Phe Val Asn Val Thr Asp Pro Ser  
 440 445 450 455

caa gtg agc cat ggc act ggc ttc acg tcc ttt ggc tta ctc aaa ctc 1444  
 Gln Val Ser His Gly Thr Gly Phe Thr Ser Phe Gly Leu Leu Lys Leu  
 460 465 470

tgaacagtgt caccttcgag gctgtgtgg agctgacgct gggagtcttc ataatacagc 1504

acaggcttaa gcccaattat acactccaag gcatgtagaa ctggtacc 1552

<210> 2

<211> 471

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Murine  
 surfactant protein D (without the CRD) fused to  
 the extracellular portion of human CD40L

<400> 2

Met Leu Pro Phe Leu Ser Met Leu Val Leu Val Gln Pro Leu Gly  
1 5 10 15

Asn Leu Gly Ala Glu Met Lys Ser Leu Ser Gln Arg Ser Val Pro Asn  
20 25 30

Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly  
35 40 45

Arg Asp Gly Arg Asp Gly Arg Glu Gly Pro Arg Gly Glu Lys Gly Asp  
50 55 60

Pro Gly Leu Pro Gly Pro Met Gly Leu Ser Gly Leu Gln Gly Pro Thr  
65 70 75 80

Gly Pro Val Gly Pro Lys Gly Glu Asn Gly Ser Ala Gly Glu Pro Gly  
85 90 95

Pro Lys Gly Glu Arg Gly Leu Ser Gly Pro Pro Gly Leu Pro Gly Ile  
100 105 110

Pro Gly Pro Ala Gly Lys Glu Gly Pro Ser Gly Lys Gln Gly Asn Ile  
115 120 125

Gly Pro Gln Gly Lys Pro Gly Pro Lys Gly Glu Ala Gly Pro Lys Gly  
130 135 140

Glu Val Gly Ala Pro Gly Met Gln Gly Ser Thr Gly Ala Lys Gly Ser  
145 150 155 160

Thr Gly Pro Lys Gly Glu Arg Gly Ala Pro Gly Val Gln Gly Ala Pro  
165 170 175

Gly Asn Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Gln Gly  
180 185 190

Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val  
195 200 205

Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala  
210 215 220

Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu  
225 230 235 240

Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly  
245 250 255

His Arg Arg Leu Asp Lys Ile Glu Asp Glu Arg Asn Leu His Glu Asp  
260 265 270

Phe Val Phe Met Lys Thr Ile Gln Arg Cys Asn Thr Gly Glu Arg Ser  
275 280 285

Leu Ser Leu Leu Asn Cys Glu Glu Ile Lys Ser Gln Phe Glu Gly Phe  
290 295 300

Val Lys Asp Ile Met Leu Asn Lys Glu Glu Thr Lys Lys Glu Asn Ser  
305 310 315 320

Phe Glu Met Gln Lys Gly Asp Gln Asn Pro Gln Ile Ala Ala His Val  
325 330 335

Ile Ser Glu Ala Ser Ser Lys Thr Thr Ser Val Leu Gln Trp Ala Glu  
340 345 350

Lys Gly Tyr Tyr Thr Met Ser Asn Asn Leu Val Thr Leu Glu Asn Gly  
355 360 365

Lys Gln Leu Thr Val Lys Arg Gln Gly Leu Tyr Tyr Ile Tyr Ala Gln  
370 375 380

Val Thr Phe Cys Ser Asn Arg Glu Ala Ser Ser Gln Ala Pro Phe Ile  
385 390 395 400

Ala Ser Leu Cys Leu Lys Ser Pro Gly Arg Phe Glu Arg Ile Leu Leu  
405 410 415

Arg Ala Ala Asn Thr His Ser Ser Ala Lys Pro Cys Gly Gln Gln Ser  
420 425 430

Ile His Leu Gly Gly Val Phe Glu Leu Gln Pro Gly Ala Ser Val Phe  
435 440 445

Val Asn Val Thr Asp Pro Ser Gln Val Ser His Gly Thr Gly Phe Thr  
450 455 460

Ser Phe Gly Leu Leu Lys Leu  
465 470

<210> 3

<211> 1574

<212> DNA

<213> Artificial Sequence

<220>

<221> 5'UTR

<222> (7)..(31)

<223> 5' UTR taken from rat sequence for surfactant  
protein D

<220>

<221> sig\_peptide

<222> (32)..(88)

<223> Signal peptide from murine surfactant protein D



<220>  
<221> CDS  
<222> (32)..(1534)

<220>  
<221> misc\_feature  
<222> (32)..(800)  
<223> Murine surfactant protein D including hub region,  
collagenous portion, and neck, but excluding  
carbohydrate recognition domain (CRD)

<220>  
<221> misc\_feature  
<222> (801)..(1534)  
<223> Murine RANKL/TRANSE extracellular region,  
including stalk

<300>  
<301> Motwani, M  
White, R A.  
Guo, N  
Dowler, L L.  
Tauber, A I.  
Motwani, M  
<302> Mouse surfactant protein-D. cDNA cloning,  
characterization, and gene localization to chromosome  
14.  
<303> J. Immunol.  
<304> 155  
<305> 12  
<306> 5671-5677  
<307> 1995  
<313> 32 TO 800

<300>  
<301> Anderson, D M.  
Maraskovsky, E  
Billingsley, W L.  
Dougall, W C.  
<302> A homologue of the TNF receptor and its ligand enhance  
T-cell growth and dendritic-cell function.  
<303> Nature  
<304> 390  
<305> 6656  
<306> 175-179  
<307> 1997  
<313> 801 TO 1534

<400> 3  
gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg 52  
Met Leu Pro Phe Leu Ser Met

ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag 100  
 Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys  
 10 15 20

agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt 148  
 Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys  
 25 30 35

agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga 196  
 Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg  
 40 45 50 55

gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg 244  
 Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met  
 60 65 70

ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga 292  
 Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly  
 75 80 85

gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta 340  
 Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu  
 90 95 100

agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa 388  
 Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu  
 105 110 115

ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt 436  
 Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly  
 120 125 130 135

cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg 484  
 Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met  
 140 145 150

caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga 532  
 Gln Gly Ser Thr Gly Ala Lys Gly Ser Thr Gly Pro Lys Gly Glu Arg  
 155 160 165

ggt gcc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga 580  
 Gly Ala Pro Gly Val Gln Gly Ala Pro Gly Asn Ala Gly Ala Ala Gly  
 170 175 180

cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc 628  
 Pro Ala Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Ser Arg Gly Pro  
 185 190 195

cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa 676  
 Pro Gly Leu Lys Gly Asp Arg Gly Val Pro Gly Asp Arg Gly Ile Lys  
 200 205 210 215

ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag 724  
 Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu

[illegible]

gtg tat gtc gtt aaa acc agc atc aaa atc cca agt tct cat aac ctg 1348  
Val Tyr Val Val Lys Thr Ser Ile Lys Ile Pro Ser Ser His Asn Leu  
425 430 435

atg aaa gga ggg agc acg aaa aac tgg tgc ggc aat tct gaa ttc cac 1396  
Met Lys Gly Gly Ser Thr Lys Asn Trp Ser Gly Asn Ser Glu Phe His  
440 445 450 455

ttt tat tcc ata aat gtt ggg gga ttt ttc aag ctc cga gct ggt gaa 1444  
Phe Tyr Ser Ile Asn Val Gly Gly Phe Phe Lys Leu Arg Ala Gly Glu  
460 465 470

gaa att agc att cag gtg tcc aac cct tcc ctg ctg gat ccg gat caa 1492  
Glu Ile Ser Ile Gln Val Ser Asn Pro Ser Leu Leu Asp Pro Asp Gln  
475 480 485

gat gcg acg tac ttt ggg gct ttc aaa gtt cag gac ata gac 1534  
Asp Ala Thr Tyr Phe Gly Ala Phe Lys Val Gln Asp Ile Asp  
490 495 500

tgagactcat ttctgtgaac attagcggcc gctaaactat 1574

<210> 4  
<211> 501  
<212> PRT  
<213> Artificial Sequence

<400> 4  
Met Leu Pro Phe Leu Ser Met Leu Val Leu Leu Val Gln Pro Leu Gly  
1 5 10 15

Asn Leu Gly Ala Glu Met Lys Ser Leu Ser Gln Arg Ser Val Pro Asn  
20 25 30

Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly  
35 40 45

Arg Asp Gly Arg Asp Gly Arg Glu Gly Pro Arg Gly Glu Lys Gly Asp  
50 55 60

Pro Gly Leu Pro Gly Pro Met Gly Leu Ser Gly Leu Gln Gly Pro Thr  
65 70 75 80

Gly Pro Val Gly Pro Lys Gly Glu Asn Gly Ser Ala Gly Glu Pro Gly  
85 90 95

Pro Lys Gly Glu Arg Gly Leu Ser Gly Pro Pro Gly Leu Pro Gly Ile  
100 105 110

Pro Gly Pro Ala Gly Lys Glu Gly Pro Ser Gly Lys Gln Gly Asn Ile  
115 120 125

Gly Pro Gln Gly Lys Pro Gly Pro Lys Gly Glu Ala Gly Pro Lys Gly  
130 135 140

Glu Val Gly Ala Pro Gly Met Gln Gly Ser Thr Gly Ala Lys Gly Ser  
145 150 155 160

Thr Gly Pro Lys Gly Glu Arg Gly Ala Pro Gly Val Gln Gly Ala Pro  
165 170 175

Gly Asn Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Gln Gly  
180 185 190

Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val  
195 200 205

Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala  
210 215 220

Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu  
225 230 235 240

Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly  
245 250 255

Arg Ala Gln Met Asp Pro Asn Arg Ile Ser Glu Asp Ser Thr His Cys  
260 265 270

Phe Tyr Arg Ile Leu Arg Leu His Glu Asn Ala Gly Leu Gln Asp Ser  
275 280 285

Thr Leu Glu Ser Glu Asp Thr Leu Pro Asp Ser Cys Arg Arg Met Lys  
290 295 300

Gln Ala Phe Gln Gly Ala Val Gln Lys Glu Leu Gln His Ile Val Gly  
305 310 315 320

Pro Gln Arg Phe Ser Gly Ala Pro Ala Met Met Glu Gly Ser Trp Leu  
325 330 335

Asp Val Ala Gln Arg Gly Lys Pro Glu Ala Gln Pro Phe Ala His Leu  
340 345 350

Thr Ile Asn Ala Ala Ser Ile Pro Ser Gly Ser His Lys Val Thr Leu  
355 360 365

Ser Ser Trp Tyr His Asp Arg Gly Trp Ala Lys Ile Ser Asn Met Thr  
370 375 380

Leu Ser Asn Gly Lys Leu Arg Val Asn Gln Asp Gly Phe Tyr Tyr Leu  
385 390 395 400

Tyr Ala Asn Ile Cys Phe Arg His His Glu Thr Ser Gly Ser Val Pro  
405 410 415

Thr Asp Tyr Leu Gln Leu Met Val Tyr Val Val Lys Thr Ser Ile Lys  
420 425 430

Ile Pro Ser Ser His Asn Leu Met Lys Gly Gly Ser Thr Lys Asn Trp  
435 440 445

Ser Gly Asn Ser Glu Phe His Phe Tyr Ser Ile Asn Val Gly Gly Phe  
450 455 460

Phe Lys Leu Arg Ala Gly Glu Glu Ile Ser Ile Gln Val Ser Asn Pro  
465 470 475 480

Ser Leu Leu Asp Pro Asp Gln Asp Ala Thr Tyr Phe Gly Ala Phe Lys  
485 490 495

Val Gln Asp Ile Asp  
500

<210> 5

<211> 1477

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: Murine  
surfactant protein D (except CRD) fused to the  
extracellular domain of murine CD40 ligand

<220>

<221> 5'UTR

<222> (7)..(31)

<223> 5' UTR from rat surfactant protein D

<220>

<221> sig\_peptide

<222> (32)..(88)

<223> Signal peptide from murine surfactant protein D

<220>

<221> CDS

<222> (32)..(1441)

<220>

<221> misc\_recomb

<222> (88)..(799)

<223> Mature murine surfactant protein D including hub  
region, collagenous portion, and neck, but  
excluding carbohydrate recognition domain (CRD)

<220>

<221> misc\_feature

<222> (800)..(1441)

<223> Murine CD40 ligand extracellular region, including  
stalk

<300>

<301> Motwani, M

White, R A.  
Guo, N  
Dowler, L L.  
Tauber, A I.  
Motwani, M

<302> Mouse surfactant protein-D. cDNA cloning,  
characterization, and gene localization to chromosome  
14.

<303> J. Immunol.

<304> 155

<305> 12

<306> 5671-5677

<307> 1995

<313> 32 TO 800

<300>

<301> Armitage, R

Fanslow, W

Sato, T A.

Clifford, K N.

<302> Molecular and biological characterization of a murine  
ligand for CD40

<303> Nature

<304> 357

<305> 6373

<306> 80-82

<307> 1992

<313> 801 TO 1441

<400> 5

gctagcgaat tccaccagga agcaatctga c atg ctg ccc ttt ctc tcc atg 52

Met Leu Pro Phe Leu Ser Met

1 5

ctt gtc ttg ctt gta cag ccc ctg gga aat ctg gga gca gaa atg aag 100

Leu Val Leu Leu Val Gln Pro Leu Gly Asn Leu Gly Ala Glu Met Lys

10 15 20

agc ctc tcg cag aga tca gta ccc aac acc tgc acc cta gtc atg tgt 148

Ser Leu Ser Gln Arg Ser Val Pro Asn Thr Cys Thr Leu Val Met Cys

25 30 35

agc cca aca gag aat ggc ctg cct ggt cgt gat gga cgg gat ggg aga 196

Ser Pro Thr Glu Asn Gly Leu Pro Gly Arg Asp Gly Arg Asp Gly Arg

40 45 50 55

gaa ggt cca cgg ggt gag aag ggt gat cca ggt ttg cca gga cct atg 244

Glu Gly Pro Arg Gly Glu Lys Gly Asp Pro Gly Leu Pro Gly Pro Met

60 65 70

ggg ctc tca ggg ttg cag ggc cct aca ggt cca gtt gga ccc aaa gga 292

Gly Leu Ser Gly Leu Gln Gly Pro Thr Gly Pro Val Gly Pro Lys Gly

75 80 85

gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta 340  
 Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu  
 90 95 100

agt gga cct cca gga ctt cca ggt att cct ggt cca gct ggg aaa gaa 388  
 Ser Gly Pro Pro Gly Leu Pro Gly Ile Pro Gly Pro Ala Gly Lys Glu  
 105 110 115

ggt ccc tct ggg aag cag ggg aac ata gga cct caa ggc aaa cca ggt 436  
 Gly Pro Ser Gly Lys Gln Gly Asn Ile Gly Pro Gln Gly Lys Pro Gly  
 120 125 130 135

cct aaa gga gag gct ggg ccc aaa gga gaa gta ggt gct cct ggc atg 484  
 Pro Lys Gly Glu Ala Gly Pro Lys Gly Glu Val Gly Ala Pro Gly Met  
 140 145 150

caa gga tct aca ggg gca aaa ggc tcc aca ggc ccc aag gga gaa aga 532  
 Gln Gly Ser Thr Gly Ala Lys Gly Ser Thr Gly Pro Lys Gly Glu Arg  
 155 160 165

ggt gcc cct ggt gtg caa gga gcc cca ggg aat gct gga gca gca gga 580  
 Gly Ala Pro Gly Val Gln Gly Ala Pro Gly Asn Ala Gly Ala Ala Gly  
 170 175 180

cct gcc gga cct gcc ggt cca cag gga gct cca ggt tcc agg ggg ccc 628  
 Pro Ala Gly Pro Ala Gly Pro Gln Gly Ala Pro Gly Ser Arg Gly Pro  
 185 190 195

cca gga ctc aag ggg gac aga ggt gtt cct gga gac aga gga atc aaa 676  
 Pro Gly Leu Lys Gly Asp Arg Gly Val Pro Gly Asp Arg Gly Ile Lys  
 200 205 210 215

ggt gaa agc ggg ctt cca gac agt gct gct ctg agg cag cag atg gag 724  
 Gly Glu Ser Gly Leu Pro Asp Ser Ala Ala Leu Arg Gln Gln Met Glu  
 220 225 230

gcc tta aaa gga aaa cta cag cgt cta gag gtt gcc ttc tcc cac tat 772  
 Ala Leu Lys Gly Lys Leu Gln Arg Leu Glu Val Ala Phe Ser His Tyr  
 235 240 245

cag aaa gct gca ttg ttc cct gat ggc cat aga aga ttg gat aag gtc 820  
 Gln Lys Ala Ala Leu Phe Pro Asp Gly His Arg Arg Leu Asp Lys Val  
 250 255 260

gaa gag gaa gta aac ctt cat gaa gat ttt gta ttc ata aaa aag cta 868  
 Glu Glu Glu Val Asn Leu His Glu Asp Phe Val Phe Ile Lys Lys Leu  
 265 270 275

aag aga tgc aac aaa gga gaa gga tct tta tcc ttg ctg aac tgt gag 916  
 Lys Arg Cys Asn Lys Gly Glu Gly Ser Leu Ser Leu Leu Asn Cys Glu  
 280 285 290 295

gag atg aga agg caa ttt gaa gac ctt gtc aag gat ata acg tta aac 964  
 Glu Met Arg Arg Gln Phe Glu Asp Leu Val Lys Asp Ile Thr Leu Asn

gag aat ggc tct gct ggc gaa cct gga cca aag gga gaa cgt gga cta 340  
 Glu Asn Gly Ser Ala Gly Glu Pro Gly Pro Lys Gly Glu Arg Gly Leu  
 90 95 100



300            305            310  
 aaa gaa gag aaa aaa gaa aac agc ttt gaa atg caa aga ggt gat gag 1012  
 Lys Glu Glu Lys Lys Glu Asn Ser Phe Glu Met Gln Arg Gly Asp Glu  
 315            320            325  
  
 gat cct caa att gca gca cac gtt gta agc gaa gcc aac agt aat gca 1060  
 Asp Pro Gln Ile Ala Ala His Val Val Ser Glu Ala Asn Ser Asn Ala  
 330            335            340  
  
 gca tcc gtt cta cag tgg gcc aag aaa gga tat tat acc atg aaa agc 1108  
 Ala Ser Val Leu Gln Trp Ala Lys Lys Gly Tyr Tyr Thr Met Lys Ser  
 345            350            355  
  
 aac ttg gta atg ctt gaa aat ggg aaa cag ctg acg gtt aaa aga gaa 1156  
 Asn Leu Val Met Leu Glu Asn Gly Lys Gln Leu Thr Val Lys Arg Glu  
 360            365            370            375  
  
 gga ctc tat tat gtc tac act caa gtc acc ttc tgc tct aat cgg gag 1204  
 Gly Leu Tyr Tyr Val Tyr Thr Gln Val Thr Phe Cys Ser Asn Arg Glu  
 380            385            390  
  
 cct tcg agt caa cgc cca ttc atc gtc ggc ctc tgg ctg aag ccc agc 1252  
 Pro Ser Ser Gln Arg Pro Phe Ile Val Gly Leu Trp Leu Lys Pro Ser  
 395            400            405  
  
 att gga tct gag aga atc tta ctc aag gcg gca aat acc cac agt tcc 1300  
 Ile Gly Ser Glu Arg Ile Leu Leu Lys Ala Ala Asn Thr His Ser Ser  
 410            415            420  
  
 tcc cag ctt tgc gag cag cag tct gtt cac ttg ggc gga gtg ttt gaa 1348  
 Ser Gln Leu Cys Glu Gln Gln Ser Val His Leu Gly Gly Val Phe Glu  
 425            430            435  
  
 tta caa gct ggt gct tct gtg ttt gtc aac gtg act gaa gca agc caa 1396  
 Leu Gln Ala Gly Ala Ser Val Phe Val Asn Val Thr Glu Ala Ser Gln  
 440            445            450            455  
  
 gtg atc cac aga gtt ggc ttc tca tct ttt ggc tta ctc aaa ctc 1441  
 Val Ile His Arg Val Gly Phe Ser Ser Phe Gly Leu Leu Lys Leu  
 460            465            470  
  
 tgaacagtgc gctgtcctag gctgcagcag ggtacc 1477

<210> 6

<211> 470

<212> PRT

<213> Artificial Sequence

<223> Description of Artificial Sequence: Murine  
 surfactant protein D (except CRD) fused to the  
 extracellular domain of murine CD40 ligand

<400> 6

Met Leu Pro Phe Leu Ser Met Leu Val Leu Leu Val Gln Pro Leu Gly  
1 5 10 15

Asn Leu Gly Ala Glu Met Lys Ser Leu Ser Gln Arg Ser Val Pro Asn  
20 25 30

Thr Cys Thr Leu Val Met Cys Ser Pro Thr Glu Asn Gly Leu Pro Gly  
35 40 45

Arg Asp Gly Arg Asp Gly Arg Glu Gly Pro Arg Gly Glu Lys Gly Asp  
50 55 60

Pro Gly Leu Pro Gly Pro Met Gly Leu Ser Gly Leu Gln Gly Pro Thr  
65 70 75 80

Gly Pro Val Gly Pro Lys Gly Glu Asn Gly Ser Ala Gly Glu Pro Gly  
85 90 95

Pro Lys Gly Glu Arg Gly Leu Ser Gly Pro Pro Gly Leu Pro Gly Ile  
100 105 110

Pro Gly Pro Ala Gly Lys Glu Gly Pro Ser Gly Lys Gln Gly Asn Ile  
115 120 125

Gly Pro Gln Gly Lys Pro Gly Pro Lys Gly Glu Ala Gly Pro Lys Gly  
130 135 140

Glu Val Gly Ala Pro Gly Met Gln Gly Ser Thr Gly Ala Lys Gly Ser  
145 150 155 160

Thr Gly Pro Lys Gly Glu Arg Gly Ala Pro Gly Val Gln Gly Ala Pro  
165 170 175

Gly Asn Ala Gly Ala Ala Gly Pro Ala Gly Pro Ala Gly Pro Gln Gly  
180 185 190

Ala Pro Gly Ser Arg Gly Pro Pro Gly Leu Lys Gly Asp Arg Gly Val  
195 200 205

Pro Gly Asp Arg Gly Ile Lys Gly Glu Ser Gly Leu Pro Asp Ser Ala  
210 215 220

Ala Leu Arg Gln Gln Met Glu Ala Leu Lys Gly Lys Leu Gln Arg Leu  
225 230 235 240

Glu Val Ala Phe Ser His Tyr Gln Lys Ala Ala Leu Phe Pro Asp Gly  
245 250 255

His Arg Arg Leu Asp Lys Val Glu Glu Glu Val Asn Leu His Glu Asp  
260 265 270

Phe Val Phe Ile Lys Lys Leu Lys Arg Cys Asn Lys Gly Glu Gly Ser  
275 280 285

Leu Ser Leu Leu Asn Cys Glu Glu Met Arg Arg Gln Phe Glu Asp Leu  
290 295 300

Val Lys Asp Ile Thr Leu Asn Lys Glu Glu Lys Lys Glu Asn Ser Phe  
305 310 315 320

Glu Met Gln Arg Gly Asp Glu Asp Pro Gln Ile Ala Ala His Val Val  
325 330 335

Ser Glu Ala Asn Ser Asn Ala Ala Ser Val Leu Gln Trp Ala Lys Lys  
340 345 350

Gly Tyr Tyr Thr Met Lys Ser Asn Leu Val Met Leu Glu Asn Gly Lys  
355 360 365

Gln Leu Thr Val Lys Arg Glu Gly Leu Tyr Tyr Val Tyr Thr Gln Val  
370 375 380

Thr Phe Cys Ser Asn Arg Glu Pro Ser Ser Gln Arg Pro Phe Ile Val  
385 390 395 400

Gly Leu Trp Leu Lys Pro Ser Ile Gly Ser Glu Arg Ile Leu Leu Lys  
405 410 415

Ala Ala Asn Thr His Ser Ser Ser Gln Leu Cys Glu Gln Gln Ser Val  
420 425 430

His Leu Gly Gly Val Phe Glu Leu Gln Ala Gly Ala Ser Val Phe Val  
435 440 445

Asn Val Thr Glu Ala Ser Gln Val Ile His Arg Val Gly Phe Ser Ser  
450 455 460

Phe Gly Leu Leu Lys Leu  
465 470

1000  
900  
800  
700  
600  
500  
400  
300  
200  
100  
0